var title_f11_17_11536="Skin biopsy lupus profundus II";
var content_f11_17_11536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus profundus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histiocytes within the fat lobule contain engulfed nuclear debris producing cells with a morphology reminiscent of an LE cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11536=[""].join("\n");
var outline_f11_17_11536=null;
var title_f11_17_11537="Poliovirus vaccine (inactivated): Patient drug information";
var content_f11_17_11537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Poliovirus vaccine (inactivated): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     see \"Poliovirus vaccine (inactivated): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/57/33684?source=see_link\">",
"     see \"Poliovirus vaccine (inactivated): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IPOL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Polio",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10028886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_polio_ipv.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11884 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11537=[""].join("\n");
var outline_f11_17_11537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028886\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=related_link\">",
"      Poliovirus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/57/33684?source=related_link\">",
"      Poliovirus vaccine (inactivated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11538="Patient information: Sex problems in women (The Basics)";
var content_f11_17_11538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/2/12322\">",
"         Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/20/16706\">",
"         Patient information: Sex as you get older (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/34/547\">",
"         Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/33/36370\">",
"         Patient information: Vulvar pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/4/32835\">",
"         Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7537\">",
"         Patient information: Vaginal dryness (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sex problems in women (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sex-problems-in-women-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H543819775\">",
"      <span class=\"h1\">",
"       What are some types of sex problems that women might have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sex problems that women might have include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having pain during sex",
"       </li>",
"       <li>",
"        Not becoming aroused or &ldquo;excited&rdquo; during sex",
"       </li>",
"       <li>",
"        Not having an orgasm during sex",
"       </li>",
"       <li>",
"        Not wanting to have sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women have problems with sex throughout their adult life. Other women develop problems later in life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543819782\">",
"      <span class=\"h1\">",
"       What causes sex problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sex problems can be caused by many things. For instance, a woman might have sex problems if she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has problems with her partner or in her relationship",
"       </li>",
"       <li>",
"        Feels unhappy or bad about herself",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sex problems can also be linked to physical events in a woman&rsquo;s life. For instance, sex can be painful for a woman in the weeks or months after she gives birth. And some women lose interest in sex as they get older or after they go through menopause. (Menopause is the time in a woman&rsquo;s life when she stops having monthly periods.)",
"     </p>",
"     <p>",
"      Certain conditions can also lead to sex problems. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medical problems, such as cancer or heart problems",
"       </li>",
"       <li>",
"        Mood problems, such as depression",
"       </li>",
"       <li>",
"        Dryness or pain in the vagina",
"       </li>",
"       <li>",
"        Pain in the lower belly, such as from an infection or past surgery",
"       </li>",
"       <li>",
"        Changes in the muscles near and around the vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sex problems can also be a side effect of certain medicines. For example, medicines to treat heart disease or depression sometimes cause sex problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543819789\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to improve my sex problem?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are having relationship problems, you can try to improve your relationship with your partner. For example, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make an effort to have more fun together by having a regular &ldquo;date night&rdquo;",
"       </li>",
"       <li>",
"        Read books or websites about sex and then talk to your partner about how to make sex better",
"       </li>",
"       <li>",
"        Go to counseling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women with pain or dryness during sex often feel better if they use vaginal lubricants. These are sold without a prescription. Examples include K-Y Jelly&reg; and Astroglide&reg;.",
"     </p>",
"     <p>",
"      It is also important to stay as healthy as possible and get treated for any medical problems you have. Women who feel healthy and happy are more likely to be happy with their sex life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543819796\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you don&rsquo;t know why you are having sex problems, your doctor or nurse can help you figure it out. He or she will talk with you and do an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543819803\">",
"      <span class=\"h1\">",
"       How are sex problems treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sex problems can be treated in different ways. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using vaginal lubricants or a prescription cream (usually estrogen) to treat vaginal dryness",
"       </li>",
"       <li>",
"        Getting treatment for mood problems, if you have mood problems",
"       </li>",
"       <li>",
"        Working with your doctor to change any medicines you take that might be causing sex problems",
"       </li>",
"       <li>",
"        Having physical therapy to loosen the muscles around your vagina so that you do not have pain during sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In addition, some women who have gone through menopause are helped by taking hormone medicines.",
"     </p>",
"     <p>",
"      Some treatments are not recommended by doctors. For example, doctors do not usually recommend that women take the medicines that men take for sex problems. Also, most doctors do not recommend that women take herbal treatments to improve sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543819810\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=see_link\">",
"       Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/20/16706?source=see_link\">",
"       Patient information: Sex as you get older (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"       Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"       Patient information: Vulvar pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"       Patient information: Vaginal dryness (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/17/11538?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15498 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11538=[""].join("\n");
var outline_f11_17_11538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819775\">",
"      What are some types of sex problems that women might have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819782\">",
"      What causes sex problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819789\">",
"      Is there anything I can do on my own to improve my sex problem?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819796\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819803\">",
"      How are sex problems treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543819810\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=related_link\">",
"      Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/20/16706?source=related_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11539="Nystatin (oral): Drug information";
var content_f11_17_11539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nystatin (oral): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=see_link\">",
"    see \"Nystatin (oral): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/52/14147?source=see_link\">",
"    see \"Nystatin (oral): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9490173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Nystatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9490176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral Nonabsorbed",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9490258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral candidiasis:",
"     </b>",
"     Suspension (swish and swallow): 400,000-600,000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intestinal infections:",
"     </b>",
"     Oral tablets: 500,000-1,000,000 units every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Powder for compounding:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     teaspoon (500,000 units) to equal approximately",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     cup of water; give 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9490256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/52/14147?source=see_link\">",
"      see \"Nystatin (oral): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Oral candidiasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Suspension:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants: 100,000 units 4 times/day; paint suspension into recesses of the mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 200,000 units 4 times/day or 100,000 units to each side of mouth 4 times/day; paint suspension into recesses of the mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 400,000-600,000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Powder for compounding:",
"     </i>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9490260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9490278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding: 50 million units (10 g); 150 million units (30 g); 500 million units (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100,000 units/mL (5 mL, 60 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500,000 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9490174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9490266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Suspension: Shake well before using. Should be swished about the mouth and retained in the mouth for as long as possible (several minutes) before swallowing. For neonates and infants, paint nystatin suspension into recesses of the mouth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9490189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible cutaneous, mucocutaneous, and oral cavity fungal infections normally caused by the",
"     <i>",
"      Candida",
"     </i>",
"     species",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9490168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nystatin may be confused with HMG-CoA reductase inhibitors (also known as \"statins\"; eg, atorvaSTATin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), Nitrostat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9490195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9490193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nystatin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9490199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9490191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adverse events in the fetus or newborn have not been reported following maternal use of vaginal nystatin during pregnancy. Absorption following oral use is poor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9490192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9887305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk is not known; however, absorption following oral use is poor.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9490280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Nystatin Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/mL (5 mL): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nystatin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500000 unit (100): $68.08",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9490226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to sterols in fungal cell membrane, changing the cell wall permeability allowing for leakage of cellular contents",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9490244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Symptomatic relief from candidiasis: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poorly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9859 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11539=[""].join("\n");
var outline_f11_17_11539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490173\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490176\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490258\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490256\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490260\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490278\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490174\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490189\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490168\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490195\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490193\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299777\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490199\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490191\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887304\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490192\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887305\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490280\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490226\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490244\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9859|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=related_link\">",
"      Nystatin (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/52/14147?source=related_link\">",
"      Nystatin (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14963?source=related_link\">",
"      Nystatin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/55/35700?source=related_link\">",
"      Nystatin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16771?source=related_link\">",
"      Nystatin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11540="Contents: Primary care infectious disease";
var content_f11_17_11540=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care infectious disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care infectious disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacterial infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39688\">",
"           Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2297\">",
"           Acute sinusitis and rhinosinusitis in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6758\">",
"           Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20058\">",
"           Antimicrobial therapy of native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/3/15417\">",
"           Aseptic meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/14/11494\">",
"           Blood cultures for the detection of bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/37/23129\">",
"           Clinical features and diagnosis of acute bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9895\">",
"           Clinical features and management of sepsis in the asplenic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38199\">",
"           Clinical manifestations and diagnosis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/52/37704\">",
"           Clinical manifestations of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27110\">",
"           Complications of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/23/375\">",
"           Diagnosis of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27285\">",
"           Diagnosis of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41352\">",
"           Diagnostic approach to infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32680\">",
"           Epidemiology and pathogenesis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27145\">",
"           Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14840\">",
"           Epidemiology, risk factors and microbiology of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31094\">",
"           Infective endocarditis: Historical and Duke criteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22810\">",
"           Initial therapy and prognosis of bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/9/1177\">",
"           Prevention of sepsis in the asplenic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14775\">",
"           Pseudomonas aeruginosa bacteremia and endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11049\">",
"           Septic arthritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/0/2055\">",
"           Suppurative (septic) thrombophlebitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33015\">",
"           Treatment and prevention of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25609\">",
"           Treatment and prevention of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2666\">",
"           Treatment and prevention of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/20/7498\">",
"           Treatment of intravascular catheter-related infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Central nervous system infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/37/23129\">",
"           Clinical features and diagnosis of acute bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27285\">",
"           Diagnosis of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22810\">",
"           Initial therapy and prognosis of bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19561\">",
"           Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25609\">",
"           Treatment and prevention of meningococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38968\">",
"           Viral encephalitis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38535\">",
"           Clinical manifestations and diagnosis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7172\">",
"           Clinical manifestations of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29305\">",
"           Clostridium difficile in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20954\">",
"           Clostridium difficile in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12296\">",
"           Diagnosis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24265\">",
"           Differential diagnosis of microbial foodborne disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43241\">",
"           Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33224\">",
"           Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14649\">",
"           Microbiology and epidemiology of salmonellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/19/18745\">",
"           Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34197\">",
"           Pathogenesis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37960\">",
"           Pathogenic Escherichia coli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29145\">",
"           Travelers' diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39334\">",
"           Treatment and prevention of Shigella infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/30/15847\">",
"           Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32980\">",
"           Atypical manifestations of hepatitis A virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31530\">",
"           Clinical manifestations and natural history of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30122\">",
"           Clinical manifestations and natural history of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14230\">",
"           Diagnosis of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2169\">",
"           Epidemiology and transmission of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4602\">",
"           Epidemiology, transmission, and prevention of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15498\">",
"           Extrahepatic manifestations of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7557\">",
"           GB virus C (hepatitis G) infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33976\">",
"           Hepatitis E virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15402\">",
"           Liver transplantation for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16474\">",
"           Liver transplantation for hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/59/35768\">",
"           Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/45/43735\">",
"           Overview of the management of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15543\">",
"           Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38841\">",
"           Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41849\">",
"           Screening for and diagnosis of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42279\">",
"           Serologic diagnosis of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14281\">",
"           Standard and pegylated interferon for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22583\">",
"           Treatment and prevention of hepatitis D virus infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/7/43129\">",
"           Acute and early HIV infection: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18151\">",
"           Acute and early HIV infection: Pathogenesis and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22808\">",
"           Acute and early HIV infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20345\">",
"           Diagnostic assays for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37273\">",
"           Immunizations in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42584\">",
"           Management of tissue wasting in patients with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11047\">",
"           Pneumococcal immunization in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33450\">",
"           Primary prevention of opportunistic infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21320\">",
"           Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13353\">",
"           The stages and natural history of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infective endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18249\">",
"           Complications and outcome of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22297\">",
"           Surgery for native valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Non-HIV immune deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8633\">",
"           Medical management of immune deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7561\">",
"           Secondary immune deficiency due to miscellaneous causes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/62/39913\">",
"           Acute otitis media in adults (suppurative and serous)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7017\">",
"           Biology and genetics of prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/10/17576\">",
"           Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1450\">",
"           Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/24/30090\">",
"           Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/53/20313\">",
"           Complications, diagnosis, and treatment of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/48/28425\">",
"           Diagnosis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/28/31176\">",
"           Diseases of the central nervous system caused by prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/30/16873\">",
"           Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26263\">",
"           Evaluation of a tick bite for possible Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39304\">",
"           Evaluation of fever in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32743\">",
"           External otitis: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12456\">",
"           External otitis: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18777\">",
"           Gingivitis and periodontitis in adults: Classification and dental treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/34/26152\">",
"           Important sites and pathogens causing infections in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40759\">",
"           Lyme carditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19096\">",
"           Marine toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9336\">",
"           Musculoskeletal manifestations of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/10/8361\">",
"           Pathophysiology and treatment of fever in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/30/489\">",
"           Principles of infection control in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27498\">",
"           Treatment of Lyme disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/44/41670\">",
"           Approach to immunizations in healthy adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31690\">",
"           Hepatitis B virus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/0/13322\">",
"           Immunizations for healthcare providers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/21/2394\">",
"           Immunizations for travel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3960\">",
"           Prevention of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13370\">",
"           Prevention of malaria infection in travelers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36200\">",
"           Prevention of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7014\">",
"           Tetanus-diphtheria toxoid vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8967\">",
"           Travel advice",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10341\">",
"           Adherence to tuberculosis treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21881\">",
"           Diagnosis and treatment of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7866\">",
"           Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23143\">",
"           Microbiology and pathogenesis of Streptococcus pneumoniae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3162\">",
"           Mycoplasma pneumoniae infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7270\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17591\">",
"           Sputum cultures for the evaluation of bacterial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38455\">",
"           Symptomatic treatment of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6761\">",
"           Tonsillectomy in adults: Surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12538\">",
"           Approach to the patient with genital ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/49/36633\">",
"           Approach to women with symptoms of vaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30602\">",
"           Bacterial vaginosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/1/15386\">",
"           Candida vulvovaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/28/10696\">",
"           Chancroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/63/37876\">",
"           Desquamative inflammatory vaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/35/26166\">",
"           Diagnosis of gonococcal infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/44/39624\">",
"           Diagnostic testing for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38217\">",
"           Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18728\">",
"           Genital Chlamydia trachomatis infections in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42728\">",
"           Genital Chlamydia trachomatis infections in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18837\">",
"           Laboratory monitoring of patients undergoing treatment for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21063\">",
"           Lymphogranuloma venereum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26312\">",
"           Neurosyphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37017\">",
"           Pathogenesis, clinical manifestations, and treatment of early syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/776\">",
"           Pathogenesis, clinical manifestations, and treatment of late syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12150\">",
"           Pathophysiology, transmission, and natural history of syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/3/19514\">",
"           Treatment of uncomplicated gonococcal infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/53/1881\">",
"           Trichomonas vaginalis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue and bone infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12071\">",
"           Approach to imaging modalities in the setting of suspected osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39269\">",
"           Pathogenesis of osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28038\">",
"           Soft tissue infections due to dog and cat bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31013\">",
"           Soft tissue infections due to human bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections (other than HIV)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33480\">",
"           Clinical features of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/20/40265\">",
"           Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/54/22377\">",
"           Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18456\">",
"           Clinical manifestations of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2378\">",
"           Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/11/43192\">",
"           Clinical presentation and diagnosis of measles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/77\">",
"           Diagnosis of varicella-zoster virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23688\">",
"           Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22278\">",
"           Epidemiology of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/33001\">",
"           Genital herpes simplex virus infection and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31018\">",
"           Infectious mononucleosis in adults and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1558\">",
"           Pathogenesis and diagnosis of viral arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/6/21608\">",
"           Postherpetic neuralgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21751\">",
"           Prevention of genital herpes virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37289\">",
"           Prevention of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36200\">",
"           Prevention of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/14/26855\">",
"           Rubella",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/51/23354\">",
"           Specific viruses that cause arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/55/24440\">",
"           The common cold in adults: Diagnosis and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30537\">",
"           The common cold in adults: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31767\">",
"           Treatment and prevention of parvovirus B19 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7690\">",
"           Treatment of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22250\">",
"           Treatment of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23110\">",
"           Treatment of varicella-zoster virus infection: Chickenpox",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33225\">",
"           Varicella-zoster virus infection in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38968\">",
"           Viral encephalitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9879\">",
"           Viral myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26455\">",
"           Virology of human papillomavirus infections and the link to cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-19429C25CA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_17_11540=[""].join("\n");
var outline_f11_17_11540=null;
var title_f11_17_11541="Simvastatin: Patient drug information";
var content_f11_17_11541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Simvastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     see \"Simvastatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/12/44231?source=see_link\">",
"     see \"Simvastatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zocor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Simvastatin&reg;;",
"     </li>",
"     <li>",
"      Ava-Simvastatin;",
"     </li>",
"     <li>",
"      CO Simvastatin;",
"     </li>",
"     <li>",
"      Dom-Simvastatin;",
"     </li>",
"     <li>",
"      JAMP-Simvastatin;",
"     </li>",
"     <li>",
"      Mint-Simvastatin;",
"     </li>",
"     <li>",
"      Mylan-Simvastatin;",
"     </li>",
"     <li>",
"      Nu-Simvastatin;",
"     </li>",
"     <li>",
"      PHL-Simvastatin;",
"     </li>",
"     <li>",
"      PMS-Simvastatin;",
"     </li>",
"     <li>",
"      Q-Simvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Simvastatin;",
"     </li>",
"     <li>",
"      ratio-Simvastatin;",
"     </li>",
"     <li>",
"      Riva-Simvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Simvastatin;",
"     </li>",
"     <li>",
"      Simvastatin-Odan;",
"     </li>",
"     <li>",
"      Taro-Simvastatin;",
"     </li>",
"     <li>",
"      Teva-Simvastatin;",
"     </li>",
"     <li>",
"      Zocor&reg;;",
"     </li>",
"     <li>",
"      ZYM-Simvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to simvastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11866 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11541=[""].join("\n");
var outline_f11_17_11541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221302\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221303\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019831\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019833\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019832\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019837\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019838\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019840\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019835\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019836\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019841\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019842\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=related_link\">",
"      Simvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/12/44231?source=related_link\">",
"      Simvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11542="Potassium chloride: Pediatric drug information";
var content_f11_17_11542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium chloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"    see \"Potassium chloride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/8/14469?source=see_link\">",
"    see \"Potassium chloride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Tab&reg;;",
"     </li>",
"     <li>",
"      Kaon-CL&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg;;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 8;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M15;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M20;",
"     </li>",
"     <li>",
"      Klor-Con&reg;/25;",
"     </li>",
"     <li>",
"      microK&reg;;",
"     </li>",
"     <li>",
"      microK&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-K&reg;;",
"     </li>",
"     <li>",
"      K-10&reg;;",
"     </li>",
"     <li>",
"      K-Dur&reg;;",
"     </li>",
"     <li>",
"      Micro-K Extencaps&reg;;",
"     </li>",
"     <li>",
"      Roychlor&reg;;",
"     </li>",
"     <li>",
"      Slo-Pot;",
"     </li>",
"     <li>",
"      Slow-K&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent doses &gt;0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     . Doses listed as mEq of",
"     <b>",
"      potassium",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Normal daily requirements: Oral, I.V.: 2-6 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of hypokalemia during diuretic therapy: 1-2 mEq/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of hypokalemia:",
"     <b>",
"      Note:",
"     </b>",
"     High variability exists in dosing/infusion rate recommendations; therapy should be guided by patient condition and specific institutional guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2-5 mEq/kg/day in divided doses; not to exceed 1-2 mEq/kg as a single dose; if deficits are severe or ongoing losses are great, I.V. route should be considered preferred route of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent I.V. infusion (must be diluted prior to administration): 0.5-1 mEq/kg/dose, infuse at 0.3-0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     (maximum dose/rate: 1 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); then repeated as needed based on frequently obtained lab values; severe depletion or ongoing losses may require &gt;200% of normal daily limit needs",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"      see \"Potassium chloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent doses &gt;0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     . Doses listed as mEq of",
"     <b>",
"      potassium",
"     </b>",
"     . When using microencapsulated or wax matrix formulations, use no more than 20 mEq as a single dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Normal daily requirements: Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2-6 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40-80 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of hypokalemia during diuretic therapy: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 1-2 mEq/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20-40 mEq/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of hypokalemia:",
"     <b>",
"      Note:",
"     </b>",
"     High variability exists in dosing/infusion rate recommendations; therapy should be guided by patient condition and specific institutional guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2-5 mEq/kg/day in divided doses; not to exceed 1-2 mEq/kg as a single dose; if deficits are severe or ongoing losses are great, I.V. route should be considered preferred route of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V. infusion (must be diluted prior to administration): 0.5-1 mEq/kg/dose (maximum dose: 40 mEq) to infuse at 0.3-0.5 mEq/kg/hour (maximum dose/rate: 1 mEq/kg/hour); then repeated as needed based on frequently obtained lab values; severe depletion or ongoing losses may require &gt;200% of normal daily limit needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V. infusion: 5-10 mEq/hour (continuous cardiac monitor recommended for rates &gt;5 mEq/hour), not to exceed 40 mEq/hour; usual adult maximum per 24 hours: 400 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Potassium dosage/rate of infusion guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Serum potassium &ge;2.5 mEq/L (and &lt;desired): 10 mEq with additional doses if needed; maximum infusion rate: 10 mEq/hour; maximum 24-hour dose: 200 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Serum potassium &lt;2.5 mEq/L: Up to 40 mEq, with additional doses based upon frequent lab monitoring; maximum infusion rate: 40 mEq/hour; maximum 24-hour dose: 400 mEq; deficits at a plasma level of 2 mEq/L may be as high as 400-800 mEq of potassium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Asymptomatic, mild hypokalemia: Usual dosage range: 40-100 mEq/day divided in 2-5 doses; generally recommended to limit doses to 20-25 mEq/dose to avoid GI discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild to moderate hypokalemia: Some clinicians may administer up to 120-240 mEq/day divided in 3-4 doses; limit doses to 40-60 mEq/dose. If deficits are severe or ongoing losses are great, I.V. route should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, microencapsulated, oral: 8 mEq, 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     microK&reg;: 8 mEq [600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     microK&reg; 10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/2 NS: 10 mEq (500 mL, 1000 mL); 20 mEq (1000 mL); 30 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/3 NS: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/4 NS: 5 mEq (250 mL); 10 mEq (500 mL); 20 mEq (1000 mL); 40 mEq (1000 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     LR: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     NS: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection [highly concentrated]: 10 mEq (50 mL, 100 mL); 20 mEq (50 mL, 100 mL); 30 mEq (100 mL); 40 mEq (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 2 mEq/mL (5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 2 mEq/mL (5 mL, 10 mL, 15 mL [DSC], 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg;: 20 mEq/packet (30s, 100s) [sugar free; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg;/25: 25 mEq/packet (30s, 100s) [sugar free; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 20 mEq/15 mL (15 mL, 30 mL, 473 mL, 480 mL); 40 mEq/15 mL (15 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, microencapsulated, oral: 8 mEq, 10 mEq, 20 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M15: 15 mEq [scored; 1125 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M20: 20 mEq [scored; 1500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, wax matrix, oral: 8 mEq, 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Tab&reg;: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaon-CL&reg; 10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; 8: 8 mEq [600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; 10: 10 mEq [750 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1032236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Sustained release and wax matrix tablets (K-Tab&reg;, Kaon-Cl-10&reg;, Klor-Con&reg;) should be swallowed whole, do not crush or chew; administer with food; powder (Klor-Con&reg;) should be dissolved in 4-5 ounces of water or juice; capsule (microK&reg;) should be swallowed whole, do not chew; may also be opened and contents sprinkled on a spoonful of applesauce or pudding and swallowed immediately without chewing; do not administer liquid formulations full strength, must be diluted in 2-6 parts of water or juice. Klor-Con&reg; M tablet may be broken in half and each half swallowed separately; the whole tablet may be dissolved in approximately 4 ounces of water (allow approximately 2 minutes to dissolve, stir well, and drink immediately).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Potassium must be diluted prior to parenteral administration; maximum recommended concentration (peripheral line): 80 mEq/L; maximum recommended concentration (central line): 150 mEq/L or 15 mEq/100 mL; in severely fluid-restricted patients (with central lines): 200 mEq/L or 20 mEq/100 mL has been used; maximum rate of infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1032225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sodium chloride 3%;",
"     <b>",
"      variable compatibility (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, mannitol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alatrofloxacin, aldesleukin, allopurinol, amifostine, aminophylline, amiodarone, ampicillin, atropine, aztreonam, betamethasone sodium phosphate, calcium gluconate, chlordiazepoxide, chlorpromazine, ciprofloxacin, cisatracurium, cladribine, clarithromycin, cyanocobalamin, dexamethasone sodium phosphate, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin liposome, droperidol, edrophonium, enalaprilat, epinephrine, esmolol, estrogens (conjugated), ethacrynate, etoposide, famotidine, fentanyl, fentanyl and droperidol, filgrastim, fludarabine, fluorouracil, furosemide, gatifloxacin, gemcitabine, granisetron, heparin, hydralazine, idarubicin, inamrinone, indomethacin, insulin (regular), isoproterenol, kanamycin, labetalol, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, menadiol, meperidine, methoxamine, methylergonovine, midazolam, milrinone, minocycline, morphine, neostigmine, norepinephrine, ondansetron, oxacillin, oxytocin, paclitaxel, penicillin G potassium, pentazocine, phytonadione, piperacillin/tazobactam, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, teniposide, theophylline, thiotepa, tirofiban, trimethaphan, trimethobenzamide, vinorelbine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, diazepam, ergotamine, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Methylprednisolone sodium succinate, promethazine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed: Compatible:",
"     </b>",
"     Aminophylline, amiodarone, atracurium, bretylium, calcium gluconate, cefepime, ceftazidime, chloramphenicol, cimetidine, ciprofloxacin, clindamycin, corticotropin, cytarabine, dimenhydrinate, dopamine, enalaprilat, erythromycin lactobionate, floxacillin, fluconazole, foscarnet, fosphenytoin, furosemide, heparin, hydrocortisone sodium succinate, hydrocortisone sodium succinate with isoproterenol, lidocaine, metaraminol, methyldopate, metoclopramide, mitoxantrone, nafcillin, norepinephrine, oxacillin, penicillin G potassium, penicillin G potassium with vitamin B complex with C, phenylephrine, piperacillin, propafenone, ranitidine, sodium bicarbonate, thiopental, vancomycin, verapamil, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amikacin, dobutamine, etoposide with cisplatin and mannitol, penicillin G sodium",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1032222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Kaon-Cl-10&reg; may be confused with kaolin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       KCl may be confused with HCl",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Klor-Con&reg; may be confused with Klaron&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       microK&reg; may be confused with Macrobid&reg;, Micronase",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Consider special storage requirements for intravenous potassium salts; I.V. potassium salts have been administered IVP in error, leading to fatal outcomes.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/discomfort, diarrhea, flatulence, GI bleeding (oral), GI obstruction (oral), GI perforation (oral), nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the potassium supplement; severe renal impairment, untreated Addison's disease, heat cramps, hyperkalemia, severe tissue trauma; solid oral dosage forms are contraindicated in patients in whom there is a structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract; an oral liquid potassium preparation should be used in patients with esophageal compression or delayed gastric emptying time",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4604082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac disease and/or renal disease, patients receiving potassium-sparing drugs; patients should be on a cardiac monitor during intermittent infusions for doses &gt;0.5 mEq/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1032210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium chloride injection should be administered only in patients with adequate urine flow; injection must be diluted before I.V. use and infused slowly",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5186460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004). Potassium supplementation (that does not cause maternal hyperkalemia) would not be expected to cause adverse fetal events.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, glucose, chloride, pH, urine output (if indicated), cardiac monitor [if intermittent I.V. infusion or potassium I.V. infusion rates &gt;0.5 mEq/kg/hour or &gt;10 mEq/hour (adults)]",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1032226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal, and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1032227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from upper GI tract; enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4604297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypokalemia is highly arrhythmogenic, particularly in the setting of ischemia or digitalis toxicity. ECG evidence of hypokalemia includes flattening of the T wave. As the T wave shrinks, U waves may appear. There is no prolongation of the QT interval. Hyperkalemia may present as tall peaked symmetrical T waves. S-T elevation may present in severe hyperkalemia. QRS complex progressively widens with eventual apparent sine waves on the ECG. Hyperkalemia will also induce cardiac slowing and AV conduction abnormalities.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamill RJ, Robinson LM, Wexler HR, et al, &ldquo;Efficacy and Safety of Potassium Infusion Therapy in Hypokalemic Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1991, 19(5):694-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11542/abstract-text/2026032/pubmed\" id=\"2026032\" target=\"_blank\">",
"        2026032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khilnani P, &ldquo;Electrolyte Abnormalities in Critically Ill Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1992, 20(2):241-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11542/abstract-text/1737458/pubmed\" id=\"1737458\" target=\"_blank\">",
"        1737458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13037 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11542=[""].join("\n");
var outline_f11_17_11542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211820\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211821\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032206\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444785\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032231\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211804\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211789\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032236\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032225\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032222\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032207\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211843\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032209\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4604082\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032210\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299917\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211800\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5186460\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032239\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032226\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032227\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4604297\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=related_link\">",
"      Potassium chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/8/14469?source=related_link\">",
"      Potassium chloride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11543="Eltrombopag: Drug information";
var content_f11_17_11543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eltrombopag: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/19/4405?source=see_link\">",
"    see \"Eltrombopag: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6815164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6809750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Promacta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Revolade&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6815168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor;",
"     </li>",
"     <li>",
"      Thrombopoietic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6815288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immune (idiopathic) thrombocytopenic purpura (ITP):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Use the lowest dose to achieve and maintain platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     as needed to reduce the risk of bleeding. Discontinue if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum daily dose of 75 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity [eg, Chinese, Japanese, Korean, Taiwanese]); dose should be titrated based on platelet response. Maximum dose: 75 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosage adjustment based on platelet response:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (&ge;2 weeks after treatment initiation or a dose increase):  Increase daily dose by 25 mg (if taking 12.5 mg once daily, increase dose to 25 mg once daily prior to increasing the dose amount by 25 mg daily); maximum: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &ge;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and &le;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (at any time): Reduce daily dose by 25 mg; reassess in 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &gt;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold dose; assess platelet count twice weekly; when platelet count &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume with the daily dose reduced by 25 mg  (if taking 25 mg once daily, resume with 12.5 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &gt;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     after 2 weeks at the lowest dose: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hepatitis C-associated thrombocytopenia:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Use the lowest dose to achieve the target platelet count necessary to initiate antiviral therapy or to avoid dose reductions of peginterferon during antiviral therapy. Discontinue when antiviral therapy is stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 25 mg once daily; dose should be titrated based on platelet response. Maximum dose: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <i>",
"      Dosage adjustment based on platelet response:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (after at least 2 weeks): Increase daily dose by 25 mg every 2 weeks; maximum dose: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &ge;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and &le;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (at any time): Reduce daily dose by 25 mg; reassess in 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &gt;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold dose; assess platelet count twice weekly; when platelet count &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , resume with the daily dose reduced by 25 mg  (if taking 25 mg once daily, resume with 12.5 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Platelet count &gt;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     after 2 weeks at the lowest dose: Discontinue treatment",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6815289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6815290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6815291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Adjustment for hepatic impairment prior to initiating treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      ITP:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Mild, moderate, or severe impairment (Child-Pugh classes A, B, or C): Initial: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Patients of East-Asian ethnicity with hepatic impairment (Child-Pugh classes A, B, or C): Initial: 12.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Chronic hepatitis C-associated thrombocytopenia:",
"     </i>",
"     Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Adjustment for hepatic impairment during treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      ITP:",
"     </i>",
"     Hepatic impairment (Child-Pugh classes A, B, or C) after treatment initiation or after dose increases: Wait 3 weeks (instead of 2 weeks) prior to increasing dose for platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      ITP and chronic hepatitis C-associated thrombocytopenia:",
"     </i>",
"     ALT levels &ge;3 times the upper limit of normal (ULN) in patients with normal hepatic function or &ge;3 times baseline in those with pre-existing transaminase elevations",
"     <b>",
"      and",
"     </b>",
"     which are progressive, persistent (&ge;4 weeks), accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation: Discontinue treatment. Treatment reinitiation is not recommended, but if determined to be clinically beneficial, may cautiously resume treatment; monitor ALT weekly during dosage titration; permanently discontinue if ALT elevations persist, worsen or recur.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6815297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Promacta&reg;: 12.5 mg, 25 mg, 50 mg, 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6815166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088990.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088990.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6815293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach, 1 hour before or 2 hours after a meal. Do not administer concurrently with antacids, foods high in calcium, or minerals (eg, iron, calcium, aluminum, magnesium, selenium, zinc); separate by at least 4 hours. Do not administer more than one dose within 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6815170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) at risk for bleeding who have had insufficient response to corticosteroids, immune globulin, or splenectomy; treatment of thrombocytopenia in patients with chronic hepatitis C in order to allow and maintain interferon-based therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6815188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions and incidences reported are associated with ITP unless otherwise indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (chronic hepatitis C 30%), fatigue (4%; chronic hepatitis C 28%), headache (10%; chronic hepatitis C 21%), insomnia (chronic hepatitis C 16%), chills (chronic hepatitis C 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (chronic hepatitis C 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (9%; chronic hepatitis C 19%), nausea (4% to 9%; chronic hepatitis C 19%), appetite decreased (chronic hepatitis C 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Myelofibrosis (bone marrow biopsy: Grade &le;1: 93%; grade 2: 7%; grade 3: &lt;3%) anemia (chronic hepatitis C 40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Liver function tests abnormal (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (chronic hepatitis C 16%), myalgia (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (chronic hepatitis C 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (3%; chronic hepatitis C 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (chronic hepatitis C 10%), thrombosis (chronic hepatitis C 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (2%; chronic hepatitis C 10%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (6%), xerostomia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Rebound thrombocytopenia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Ascites and encephalopathy (chronic hepatitis C 7%), hyperbilirubinemia (6% to 8%), ALT increased (5% to 6%), AST increased (4%), alkaline phosphatase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), paresthesia (3%), musculoskeletal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Cataract (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (7%), oropharyngeal pain (4%), pharyngitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bone marrow fibrosis, bone marrow reticulin fiber deposits, hemorrhage (due to thrombocytopenia or rebound thrombocytopenia), non-Hodgkin&rsquo;s lymphoma, portal vein thrombosis, thrombotic/thromboembolic complications, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6815176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6815177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Box warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic hepatitis C: See &ldquo;Disease-related concerns&rdquo; below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: See &ldquo;Concerns related to adverse effects&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow reticulin: May increase the risk for bone marrow reticulin formation or progression; collagen fibrosis (not associated with cytopenias) was observed in clinical trials. In an extension study, myelofibrosis (&le; grade 1) was observed in a majority of bone marrow biopsies performed after 1 year of treatment. Risk of bone marrow fibrosis with clinical ramifications has not been excluded in clinical trials. Monitor peripheral blood smear for cellular morphologic abnormalities; analyze CBC monthly; discontinue treatment with onset of new or worsening abnormalities (eg, teardrop and nucleated RBC, immature WBC) or cytopenias and consider bone marrow biopsy (with staining for fibrosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cataract formation: Cataract formation or worsening was observed in clinical trials. Monitor regularly for signs and symptoms of cataracts; obtain ophthalmic exam at baseline and during therapy. Use with caution in patients at risk for cataracts (eg, advanced age, long-term glucocorticoid use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause hepatotoxicity; obtain ALT, AST, and bilirubin prior to treatment initiation, every 2 weeks during adjustment phase, then monthly (after stable dose established). Obtain fractionation for elevated bilirubin levels. Repeat abnormal liver function tests within 3-5 days; if confirmed abnormal, monitor weekly until resolves, stabilizes, or returns to baseline. Discontinue treatment for ALT levels &ge;3 times the upper limit of normal (ULN) in patients with normal hepatic function, or &ge;3 times baseline in those with pre-existing transaminase elevations and which are progressive, or persistent (&ge;4 weeks), or accompanied by increased direct bilirubin, or accompanied by clinical signs of liver injury or evidence of hepatic decompensation",
"     </b>",
"     . Reinitiation is not recommended; hepatotoxicity usually recurred with retreatment after therapy interruption; however, if the benefit of treatment outweighs the hepatotoxicity risk, initiate carefully, and monitor liver function tests weekly during the dose adjustment phase. Permanently discontinue if hepatotoxicity recurs with rechallenge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy/tumorigenicity: Stimulation of cell surface thrombopoietin (TPO) receptors may increase the risk for hematologic malignancies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: Thromboembolism (venous or arterial) may occur with excess increases in platelet levels. Use with caution in patients with known risk factors for thromboembolism (eg, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). Thrombotic events, primarily involving the portal venous system, were more commonly seen in eltrombopag-treated chronic hepatitis C patients with thrombocytopenia (when compared to placebo). In addition, portal venous thrombosis was reported in a study of non-ITP thrombocytopenic patients with chronic liver disease undergoing elective invasive procedures receiving eltrombopag 75 mg once daily for 14 days as a preparative regimen to reduce platelet transfusions (not an FDA-approved indication).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic hepatitis C infection:",
"     <b>",
"      [U.S. Boxed Warning]: May increase risk of hepatic decompensation when used in combination with interferon and ribavirin in patients with chronic hepatitis C.",
"     </b>",
"     In clinical trials, patients with low albumin (&lt;3.5 g/dL) or a Model for End-Stage Liver Disease (MELD) score &ge;10 at baseline had an increased risk of hepatic decompensation; closely monitor these patients during therapy. If antiviral therapy is discontinued for hepatic decompensation according to interferon/ribavirin recommendations, eltrombopag should also be discontinued. Indirect hyperbilirubinemia is commonly observed with eltrombopag when used in combination with peginterferon and ribavirin. In addition, ascites, encephalopathy, and thrombotic events were reported more frequently than placebo in chronic hepatitis C trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Clearance may be reduced in patients with hepatic impairment; use with caution; reduced starting doses are recommended in patients with ITP who have hepatic impairment (no initial dose reductions are necessary in patients with chronic hepatitis C-related thrombocytopenia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution with renal impairment (any degree) and monitor closely; initial dosage adjustment is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antacids/calcium/cation mineral supplements: May reduce eltrombopag levels; allow at least 4 hours between dosing of eltrombopag and antacids, minerals (eg, iron, calcium, aluminum, magnesium, selenium, zinc), or foods high in calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; East-Asian ethnicity (eg, Chinese, Japanese, Korean, Taiwanese): May have greater drug exposure (compared to non-East Asians); therapy should be initiated with lower starting doses in ITP patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Do not use to normalize platelet counts.",
"     <i>",
"      ITP:",
"     </i>",
"     Indicated only when the degree of thrombocytopenia and clinical conditions increase the risk for bleeding in patients with chronic immune ITP; use the lowest dose necessary to achieve and maintain platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Discontinue if platelet count does not respond to a level to avoid clinically important bleeding after 4 weeks at the maximum recommended dose.",
"     <i>",
"      Chronic hepatitis C-associated thrombocytopenia:",
"     </i>",
"     Use only when thrombocytopenia prevents the initiation and maintenance of interferon-based therapy; discontinue if antiviral therapy is discontinued. Safety and efficacy have not been established when combined with direct acting antiviral medications approved for chronic hepatitis C genotype 1 infection therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F6815843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C8 (minor), UGT1A1, UGT1A3;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), SLCO1B1, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B15, UGT2B7",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6815844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any multivitamin that contains polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OATP1B1/SLCO1B1 Substrates: Eltrombopag may increase the serum concentration of OATP1B1/SLCO1B1 Substrates.  Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Eltrombopag may increase the serum concentration of Rosuvastatin.  Management: According to eltrombopag prescribing information, consideration should be given to a preventative 50% reduction in rosuvastatin adult dose when starting this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selenium: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., selenium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products such as sucralfate) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., zinc-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6815198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food, especially dairy products, may decrease the absorption of eltrombopag. Management: Take on an empty stomach at least 1 hour before or 2 hours after a meal. Separate intake from antacids, foods high in calcium, or minerals (eg, iron, calcium, aluminum, magnesium, selenium, zinc) by at least 4 hours.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6815171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6815172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Use during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus. A Promacta&reg; pregnancy registry has been established to monitor outcomes of women exposed to eltrombopag during pregnancy (1-888-825-5249).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6815174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6815175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if eltrombopag is excreted in breast milk. Due to the potential for serious adverse effects in the nursing infant, the decision to discontinue therapy or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6815210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach (1 hour before or 2 hours after a meal). Food, especially dairy products, may decrease the absorption of eltrombopag; allow at least 4 hours between dosing of eltrombopag and polyvalent cation intake (eg, dairy products, calcium-rich foods, multivitamins with minerals).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Promacta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (30): $2967.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $2967.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $5934.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $8901.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6815295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, including ALT, AST, and bilirubin (baseline, every 2 weeks during dosage titration, then monthly; evaluate abnormal liver function tests within 3-5 days; monitor weekly until abnormalities resolve, stabilize, or return to baseline or if retreating [not recommended] after therapy interruption for hepatotoxicity); bilirubin fractionation (for elevated bilirubin); CBC with differential and platelet count (weekly at initiation and during dosage titration, then monthly when stable; after cessation, monitor weekly for &ge;4 weeks); peripheral blood smear (baseline and monthly when stable), bone marrow biopsy with staining for fibrosis (if peripheral blood smear reveals abnormality); ophthalmic exam (baseline and during treatment)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6815285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target platelet count (with treatment) of 50,000-200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelet life span: 8-11 days",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rebozet (ID);",
"     </li>",
"     <li>",
"      Revolade (AR, AT, AU, BE, BR, CH, CN, CZ, DK, EE, FR, GB, HK, IE, IL, JP, MY, NO, NZ, PL, PT, RU, SE, SG, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6815283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thrombopoietin (TPO) nonpeptide agonist which increases platelet counts by binding to and activating the human TPO receptor. Activates intracellular signal transduction pathways to increase proliferation and differentiation of marrow progenitor cells. Does not induce platelet aggregation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6815201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Platelet count increase: Within 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak platelet count increase: 14-16 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Platelets return to baseline: 1-2 weeks after last dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive hepatic metabolism; via CYP 1A2, 2C8 oxidation and UGT 1A1, 1A3 glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~21-32 hours in healthy individuals; ~26-35 hours in patients with ITP",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~59%, 20% as unchanged drug, 21% glutathione-related conjugates); urine (31%, 20% glucuronide of the phenypyrazole moiety)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bussel JB, Cheng G, Saleh MN, et al, &ldquo;Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(22):2237-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/18046028/pubmed\" id=\"18046028\" target=\"_blank\">",
"        18046028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bussel JB, Provan D, Shamsi T, et al, &ldquo;Effect of Eltrombopag on Platelet Counts and Bleeding During Treatment of Chronic Idiopathic Thrombocytopenic Purpura: A Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9664):641-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/19231632/pubmed\" id=\"19231632\" target=\"_blank\">",
"        19231632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheng G, Saleh MN, Marcher C, et al, &ldquo;Eltrombopag for Management of Chronic Immune Thrombocytopenia (RAISE): A 6-Month, Randomised, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 377(9763):393-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/20739054/pubmed\" id=\"20739054\" target=\"_blank\">",
"        20739054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuker A, \"Toxicities of the Thrombopoietic Growth Factors,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2010, 47(3):289-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/20620441/pubmed\" id=\"20620441\" target=\"_blank\">",
"        20620441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenkins JM, Williams D, Deng Y, et al, &ldquo;Phase 1 Clinical Study of Eltrombopag, An Oral, Nonpeptide Thrombopoietin Receptor Agonist,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(11):4739-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/17327409/pubmed\" id=\"17327409\" target=\"_blank\">",
"        17327409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuter DJ, &ldquo;New Thrombopoietic Growth Factors,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(11):4607-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/17289815/pubmed\" id=\"17289815\" target=\"_blank\">",
"        17289815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthys G, Park JW, McGuire S, et al, &ldquo;Eltrombopag Does Not Affect Cardiac Repolarization: Results From a Definitive QTc Study in Healthy Subjects,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2010, 70(1):24-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/20642544/pubmed\" id=\"20642544\" target=\"_blank\">",
"        20642544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McHutchison JG, Dusheiko G, Schiffman ML, et al, &ldquo;Eltrombopag for Thrombocytopenia in Patients With Cirrhosis Associated With Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(22):2227-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/18046027/pubmed\" id=\"18046027\" target=\"_blank\">",
"        18046027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olnes MJ, Scheinberg P, Calvo KR, et al, &ldquo;Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(1):11-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/22762314/pubmed\" id=\"22762314\" target=\"_blank\">",
"        22762314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pecci A, Gresele P, Klersy C, et al, &ldquo;Eltrombopag for the Treatment of the Inherited Thrombocytopenia Deriving From MYH9 Mutations,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(26):5832-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/20844233/pubmed\" id=\"20844233\" target=\"_blank\">",
"        20844233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saleh MN, Bussel JB, Cheng G, et al, &ldquo;Safety and Efficacy of Eltrombopag for Treatment of Chronic Immune Thrombocytopenia: Results of the Long-Term, Open-Label EXTEND Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2013, 121(3):537-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/23169778/pubmed\" id=\"23169778\" target=\"_blank\">",
"        23169778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams DD, Peng B, Bailey CK, Effects of Food and Antacids on the Pharmacokinetics of Eltrombopag in Healthy Adult Subjects: Two Single-Dose, Open-Label, Randomized-Sequence, Crossover Studies,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(4):764-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/17/11543/abstract-text/19446149/pubmed\" id=\"19446149\" target=\"_blank\">",
"        19446149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9051 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11543=[""].join("\n");
var outline_f11_17_11543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815164\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6809750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817171\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815168\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815288\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815289\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815290\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815291\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815297\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874620\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815293\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815170\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815188\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815176\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815177\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815843\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815844\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815198\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815171\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815172\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815174\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815175\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815210\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321880\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815295\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815285\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961943\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815283\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815201\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/19/4405?source=related_link\">",
"      Eltrombopag: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11544="Role of ultrasound";
var content_f11_17_11544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Role of ultrasound in assessing extent of disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 472px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound shows three additional cancers in the same breast. An irregular solid hypoechoic nodule in the 12:00 o'clock position (Panel A) corresponds to a nodule seen on mammogram and palpated on clinical examination. Three additional hypoechoic nodules (Panels B, C, and D) are seen between 2:00 and 11:00 o'clock positions that are non palpable. Presurgical knowledge of additional lesions is important in treatment planning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11544=[""].join("\n");
var outline_f11_17_11544=null;
var title_f11_17_11545="Cardiac resynchronization therapy in heart failure: Implantation and other considerations";
var content_f11_17_11545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Leslie A Saxon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Teresa DeMarco, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11545/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/17/11545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapies, such as angiotensin converting enzyme inhibitors, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , have led to marked improvements in both symptom control and overall survival in patients with heart failure (HF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Implanted devices, such as cardioverter-defibrillators (ICDs) and pacemakers, can also be beneficial. In particular, ICDs are now recommended for primary prevention of sudden cardiac death in selected patients with ischemic and nonischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some HF patients with bundle branch block benefit from simultaneous pacing of both ventricles (biventricular or BiV pacing) or left ventricular pacing. This approach is referred to as cardiac resynchronization therapy (CRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. CRT can be achieved with a device designed only for pacing or can be incorporated into a combination device with an ICD (",
"    <a class=\"graphic graphic_figure graphicRef79450 \" href=\"UTD.htm?15/35/15925\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CRT is recommended in patients with HF (NYHA class I-IV), severe systolic dysfunction (eg, left ventricular ejection fraction (LVEF) &le;30 to 35 percent) and intraventricular conduction delay (eg, QRS &gt;120 to 150 msec). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .) The rationale for CRT is that ventricular dyssynchrony can further impair the pump function of a failing ventricle. Resynchronization may improve pump performance and reverse the deleterious process of ventricular remodeling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The implantation technique for cardiac resynchronization therapy (CRT) and other considerations in the management of patients with HF will be reviewed here. Indications for CRT and studies evaluating standard dual-chamber pacing in HF and the possible role of CRT in patients with atrial fibrillation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=see_link\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPLANTATION TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical trials, which led to the approval of CRT in Europe and Canada, utilized an epicardial lead for LV pacing or a transvenous lead that was not specifically designed and tested for long-term LV pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Epicardial leads have a greater risk of failure to capture with chronic pacing, and placement of an epicardial LV lead requires a limited thoracotomy, which is performed under general anesthesia and associated with a greater operative risk than a completely transvenous system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of a transvenous coronary sinus lead placement for long-term LV pacing has simplified the implant procedure while markedly reducing operative risk, as demonstrated in numerous clinical trials. However, implantation of a coronary sinus catheter may result in perforation or dissection and other complications, and should be performed only by experienced operators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication with transvenous CRT implantation is inability to implant the left ventricular pacing lead successfully in the coronary vein. Additional complications include coronary sinus or coronary vein trauma, pneumothorax,",
"    <span class=\"nowrap\">",
"     diaphragmatic/phrenic",
"    </span>",
"    nerve pacing, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. There are also specific concerns with LV lead placement such as prolonged radiation exposure due to the complexity of the transvenous implantation procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/14\">",
"     14",
"    </a>",
"    ], and the theoretical risk that pacing from an LV lead may be proarrhythmic due to alterations in depolarization and repolarization sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of complications is illustrated by the following results from a review of implantation success rates and safety outcomes in 89 studies of patients undergoing CRT or CRT-ICD implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 54 studies (6123 patients) of CRT-alone devices, implantation was unsuccessful in 7 percent and 0.3 percent of patients died during implantation. During a median 6 months follow-up, 5 percent of CRT devices malfunctioned and 2 percent of patients were hospitalized for infections in the implant site. During a median follow-up of 11 months, lead problems occurred in 7 percent of CRT devices.",
"      <br/>",
"      <br/>",
"      Despite concern about a theoretical proarrhythmic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/15\">",
"       15",
"      </a>",
"      ], pooling of data from 14 randomized controlled trials did not reveal any excess risk of sudden death or noncardiac death in CRT device recipients.",
"     </li>",
"     <li>",
"      In 36 studies (5199 patients) of combined CRT-ICD devices, implantation was unsuccessful in 6 percent and 0.5 percent of patients died during implantation. Over a median 12 months follow-up, 5 percent of CRT-ICD devices malfunctioned, 1 percent of patients developed site infection, and lead problems were detected in 7 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher in-hospital mortality rates were observed in a cohort of 26887 patients undergoing ICD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRT implantation that included older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/16\">",
"     16",
"    </a>",
"    ]. Rates ranged from 0.7 to 1.2 to 2.2 percent in patients aged &lt;80, 80 to 85, and &gt;85 years.",
"   </p>",
"   <p>",
"    These complications have led some investigators to consider returning to intrathoracic procedures now that minimally invasive techniques are available. Such an approach permits more freedom of lead placement and, in an initial report of 41 patients, there were no in-hospital deaths, intraoperative complications, or failures to implant the left ventricular lead [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING OF BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic benefit (eg, improvement in NYHA class by one class or increased six minute walk distance) occurs early and has persisted through extended follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/10,11,18,19\">",
"     10,11,18,19",
"    </a>",
"    ]. This pattern is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the MIRACLE trial, most of the improvement in symptoms and quality-of-life were seen at one month [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/20\">",
"       20",
"      </a>",
"      ]; a symptomatic benefit was not assessed before three months in CARE-HF and COMPANION [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/11,21\">",
"       11,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 22 patients who underwent repeat invasive hemodynamic assessment six months after implantation, the improvements associated with CRT were maintained [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with the adverse effects observed with late interruption of CRT. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Interruption of CRT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSESSING AND OPTIMIZING RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lack of standard response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;One limitation in interpreting and comparing clinical CRT trials is disparity in response criteria. A review identified 17 different primary response criteria in the 26 most cited CRT publications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/22\">",
"     22",
"    </a>",
"    ]. Agreement among 15 of these criteria was assessed in 426 patients from the PROSPECT study. Ninety-nine percent of patients demonstrating a positive response to at least one of the 15 criteria and 94 percent were classified as nonresponders by at least one criterion. When the 15 criteria were compared, 75 percent of comparisons showed poor agreement and only 4 percent showed strong agreement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     AV delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;With CRT devices, as with standard dual chamber pacemakers, the delay between atrial and ventricular stimulation (the AV delay) can be adjusted. In standard pacemakers, the AV delay is often programmed to approximate a physiologic AV interval (eg, 160 to 180 msec) or longer to allow native AV conduction.",
"   </p>",
"   <p>",
"    Because ventricular pacing is desired in CRT, a short AV delay is often used to prevent native AV conduction (eg, 110 msec). Further adjustments in the AV delay may improve cardiac output and reduce pre-systolic mitral regurgitation in selected patients. The clinical benefit of AV optimization is not fully defined, and the best method for optimizing AV delay is not known. A small study suggested that the optimal AV delay could be defined by Doppler echocardiography; the end of the A wave (indicating the end of atrial contraction) should coincide with the onset of systolic mitral regurgitant flow (indicating the onset of ventricular contraction) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lead positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal position for the LV lead is not fully defined. Because the posterolateral wall is often the latest segment to contract in a dyssynchronous LV, it is the preferred location. Also, transvenous passage of the lead via the coronary sinus into a coronary vein constrains lead location to the lateral wall.",
"   </p>",
"   <p>",
"    The value of placing the LV pacing lead at or near the area of maximal mechanical delay, identified by tissue Doppler imaging, was assessed in a series of 54 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/24\">",
"     24",
"    </a>",
"    ]. Reverse remodeling, defined as a reduction in end-systolic volume, was significantly greater among patients in whom the LV pacing lead was placed at the site of maximal delay. Further study is required to determining the clinical benefit from tissue Doppler guided lead positioning.",
"   </p>",
"   <p>",
"    The LV pacing site was found to be a major determinant of acute hemodynamic response in a study of 35 CRT candidates with nonischemic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/25\">",
"     25",
"    </a>",
"    ]. The best pacing site for each patient was defined as the site associated with the greatest improvement in",
"    <span class=\"nowrap\">",
"     +dP/dtmax.",
"    </span>",
"    The location of the best pacing site varied greatly among the patients. Pacing at the best site yielded greater improvements in",
"    <span class=\"nowrap\">",
"     +dP/dtmax",
"    </span>",
"    than pacing the coronary sinus, the lateral LV wall, or the latest activated LV wall as determined by echocardiography. Further development and evaluation of lead position techniques are required to ascertain the value of individualized lead placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Scar burden",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations suggest that the presence, location",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of left ventricular scar may impact response to CRT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 40 patients with indications for CRT who underwent cardiac magnetic resonance imaging, 14 had a transmural posterolateral scar [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/26\">",
"       26",
"      </a>",
"      ]. These patients had a lower response rate to CRT (14 versus 81 percent of patients without posterolateral scar).",
"     </li>",
"     <li>",
"      In a series of 50 patients with indications for CRT who underwent SPECT imaging, global scar burden, number of severely scarred segments and scar burden near the LV lead were all inversely correlated with increase in LVEF after CRT [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an ECG measure of scar was associated with reduced odds of reverse remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link&amp;anchor=H27218186#H27218186\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\", section on 'Ventricular activation sequence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799294\">",
"    <span class=\"h1\">",
"     THINGS TO AVOID",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Right atrial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual-chamber pacing (right atrium and right ventricle) in patients with HF has adverse effects on outcome and is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right atrial pacing also has adverse effects in patients treated with CRT as illustrated in a crossover study of 17 patients who paced in the DDD and VDD modes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/29\">",
"     29",
"    </a>",
"    ]. Avoidance of right atrial pacing was associated with significantly greater improvements in ventricular dyssynchrony and in myocardial performance. With VDD pacing, both atria are activated via the intrinsic conduction system. In contrast, pacing of the right atrial appendage in the DDD mode leads to delayed activation of the left atrium, which may impair left ventricular preload due a reduction in the left atrial contribution. If pace compensation is used to account for this problem, there is some loss of ventricular synchrony.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interruption of CRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRT may be interrupted for a variety of reasons during long term follow-up after device implantation. In a review of 443 patients with a successfully implanted device from the VENTAK",
"    <span class=\"nowrap\">",
"     CHF/CONTAK",
"    </span>",
"    CD trial, CRT was interrupted in 161 (36 percent) during 2.5 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/30\">",
"     30",
"    </a>",
"    ]. The most common reasons for interruption of therapy were atrial tachyarrhythmias (81 patients) and loss of left ventricular capture (44 patients). In 95 percent of cases, it was possible to reinitiate CRT after appropriate intervention (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy, device reprogramming, lead repositioning).",
"   </p>",
"   <p>",
"    A study performed from analyzing data transmitted from CRT devices in over 30,000 patients found that a higher percentage of biventricular paced beats was associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/31\">",
"     31",
"    </a>",
"    ]. A significantly higher survival rate was seen in patients with &gt;98.5 percent biventricular pacing as compared to those with &le;98.5 percent biventricular pacing. These data suggest that measures to aggressively reduce native conduction and ventricular arrhythmias that prevent CRT pacing may improve the survival benefit from CRT.",
"   </p>",
"   <p>",
"    Malfunction or cessation of BiV pacemakers typically results in recurrence or exacerbation of HF. The magnitude and rapidity of the hemodynamic deterioration was illustrated in a report of 20 patients with advanced HF and functional mitral regurgitation who had received CRT for a median of 427 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/32\">",
"     32",
"    </a>",
"    ]. At 72 hours after elective temporary cessation of biventricular pacing, there was a marked decline in the maximal rate of rise of left ventricular systolic pressure (711 to 442",
"    <span class=\"nowrap\">",
"     mmHg/sec).",
"    </span>",
"    This was associated with approximately two-fold increases in mitral effective regurgitant orifice area, regurgitant volume, and regurgitant fraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link&amp;anchor=H10#H10\">",
"     \"Functional mitral regurgitation\", section on 'Cardiac resynchronization therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of BiV pacemaker malfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31302?source=see_link&amp;anchor=H22#H22\">",
"     \"Dual chamber pacing system malfunction: Evaluation and management\", section on 'Biventricular pacemakers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799302\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799422\">",
"    <span class=\"h2\">",
"     Impact on ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with left ventricular systolic dysfunction treated with CRT, a reverse remodeling response may be associated with reduction in risk of ventricular tachyarrhythmias (VTA). The risk of a first appropriate implantable cardioverter-defibrillator (ICD) therapy for a VTA (ventricular tachycardia, ventricular fibrillation, or ventricular flutter) during two year follow-up was compared between high responders to CRT-D therapy (those with &ge;25 percent reductions in left ventricular end-systolic volume at one year, n=529), low responders (those with &lt;25 percent reduction in left ventricular end-systolic volume, n=220), and ICD-only patients (n=623) enrolled in MADIT-CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/33\">",
"     33",
"    </a>",
"    ]. The cumulative probability of a first VTA was highest for low responders (28 percent), intermediate for ICD-only patients (21 percent), and lowest among high responders (12 percent). After adjustment for covariates, there was a significant 55 percent reduction in the risk of VTA in high responders compared to ICD-only patients but no significant difference between low responders and ICD-only patients. There was a nonsignificant trend toward higher risk of ventricular tachycardia among low responders compared to ICD-only patients (p=0.074).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799233\">",
"    <span class=\"h2\">",
"     Left ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above trials of CRT utilized BiV pacing to restore ventricular synchrony. However, among patients with a bundle branch block (most often LBBB), single ventricle pacing on the side of the bundle branch block is another method to restore ventricular synchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/34\">",
"     34",
"    </a>",
"    ]. The two approaches to CRT were compared directly in four randomized trials: PATH-CHF and DECREASE-HF, B-LEFT HF, and GREATER_EARTH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Of note, these trials were not powered to assess mortality or hospitalization outcomes. The three latter larger trials are summarized here:",
"   </p>",
"   <p>",
"    The DECREASE-HF trial enrolled 306 patients with NYHA class III or IV HF, an LVEF &le;35 percent and a QRS &ge;150 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/36\">",
"     36",
"    </a>",
"    ]. The patients were randomly assigned to simultaneous BiV pacing, sequential BiV pacing (ie, LV activation preceding RV activation by 20 to 80 msec) or LV pacing. The outcomes evaluated were changes in echocardiographic parameters (eg, LVEF and LV volumes). At six months, all groups had a significant improvement in these measures. The standard BiV pacing group had the greatest improvement in end-systolic dimensions, but there were no other differences in echocardiographic parameters among the three groups.",
"   </p>",
"   <p>",
"    In B-LEFT HF, 176 patients with NYHA class III or IV HF, an LVEF &le;35 percent, and a QRS &ge;130 ms received a CRT-D device and were randomly assigned to receive BiV or LV pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/37\">",
"     37",
"    </a>",
"    ]. At six months, response rates (as measured by a combination of improvement in NYHA class and reverse remodeling, improvement in HF composite score, and reduction in LV end-systolic volume of at least 10 percent) indicated that LV pacing was noninferior to BiV pacing.",
"   </p>",
"   <p>",
"    In the GREATER-EARTH trial, 121 patients with HF with an LVEF &le;35 percent and a QRS &ge;120 msec were randomly assigned to LV followed by BiV pacing or vice versa for consecutive six-month periods (after an initial run-in period of two to eight weeks with CRT off and uptitration of pharmacologic therapy as tolerated). Reverse remodeling (&ge;15 percent reduction in LV end-systolic volume) was observed in 47 percent with LV pacing and in 55 percent with BiV pacing. Clinical response (&ge;20 percent increase in exercise duration) to LV and BiV pacing was similar (48 and 55 percent). Seventeen percent of BiV nonresponders improved with LV pacing and 31 percent of LV nonresponders improved with BiV pacing.",
"   </p>",
"   <p>",
"    At present, BiV pacing is the preferred approach since there is greater evidence to support its use. The GREATER-EARTH trial provides some support for a strategy of reprogramming a BiV pacer to LV only when the response to BiV pacing is suboptimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other measures of dyssynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although direct measures of mechanical or electrical dyssynchrony have been investigated as a means of identifying responders to CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], the clinical utility of such assessment has not been established. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Significance of dyssynchrony measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of imaging modalities and electrocardiographic parameters have been evaluated as tools for quantifying LV dyssynchrony. Echocardiography including tissue Doppler imaging (TDI) has been the most widely studied and is currently the most widely used method to assess mechanical dyssynchrony in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/44-51\">",
"     44-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for performance and reporting of echocardiography for CRT were provided in the 2008 American Society of Echocardiography (ASE) consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/52\">",
"     52",
"    </a>",
"    ]. The ASE statement advises that dyssynchrony reports should NOT include a recommendation for whether a patient should undergo CRT, as this should be a case-by-case clinical decision.",
"   </p>",
"   <p>",
"    Additional methods for assessing dyssynchrony that have been investigated include cardiac magnetic resonance imaging (CMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/26,53,54\">",
"     26,53,54",
"    </a>",
"    ], myocardial strain imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/55,56\">",
"     55,56",
"    </a>",
"    ] and electrical activation patterns assessed by electrophysiologic mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Tissue Doppler imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;TDI is currently the most widely studied method for direct measurement of dyssynchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/40,41,44,46-52\">",
"     40,41,44,46-52",
"    </a>",
"    ]. Doppler echocardiography measures velocity of movement at a defined point within the heart. By measuring the velocities of myocardial movement (tissue Doppler), one can assess the timing of contraction in various segments of the left ventricle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparing the timing of contraction in different ventricular segments permits calculation of ventricular dyssynchrony. A variety of measures have been proposed, including the absolute differences in time to peak contraction and the standard deviation of the time to contraction in multiple segments (Yu index).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Significance of dyssynchrony measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous single-center studies of response to CRT in patients with HF and prolonged QRS duration found that reverse remodeling was more likely and cardiac events were less likely in patients with mechanical dyssynchrony on baseline imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/44,47,48,51,58-60\">",
"     44,47,48,51,58-60",
"    </a>",
"    ]. Furthermore, among 100 patients with TDI evidence of dyssynchrony at baseline, reverse remodeling with CRT only occurred in those whose TDI dyssynchrony assessment improved by at least 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the multicenter, prospective, nonrandomized PROSPECT study of 498 patients with standard CRT indications found that 12 echocardiographic dyssynchrony measures (including seven TDI parameters) offered only modest sensitivity (9 to 77 percent) and specificity (31 to 93 percent) to predict clinical composite score response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/62\">",
"     62",
"    </a>",
"    ]. For all the parameters, the area under the receiver-operator characteristics curve for clinical or volume response to CRT was &le;0.62. In addition, there was large variability in the analysis of the dyssynchrony parameters. Therefore, no single echocardiographic measure of dyssynchrony can be recommended to improve patient selection for CRT.",
"   </p>",
"   <p>",
"    Although echocardiographic predictor of response to CRT was identified by the PROSPECT study, observational data suggest that baseline echocardiographic features may be clinically relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort of 229 patients with NYHA class III to IV HF with left ventricular ejection fraction &le;35 percent and QRS duration &ge;120 msec were studied prior to CRT and for four years following device implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/63\">",
"       63",
"      </a>",
"      ]. Baseline evidence of left ventricular dyssynchrony (12-site Yu index &ge;32 msec, speckle tracking radial strain &ge;130 msec, or pulsed Doppler interventricular mechanical delay&ge;40 msec) was associated with a lower rate of events (death, transplantation or left ventricular assist device implantation). Yu index and radial strain dyssynchrony were independently associated with outcome in adjusted analysis. Absence of radial dyssynchrony with QRS duration of 120 to 150 was associated with a particularly poor prognosis.",
"     </li>",
"     <li>",
"      Response to cardiac resynchronization therapy may be influenced by diverse baseline factors. A study of 397 patients with ischemic heart failure found that presence of radial dyssynchrony predicted superior survival, while suboptimal lead position (location outside the latest activated segment), and evidence of myocardial scar adjacent to the left ventricular lead were independent predictors of mortality. Models incorporating these three parameters yielded incrementally improved prognostic value over a model limited to clinical variables. [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As many as 30 to 40 percent of patients with advanced HF who have a prolonged QRS duration do not have mechanical dyssynchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/65\">",
"     65",
"    </a>",
"    ]. As noted in the 2008 American Society of Echocardiography consensus statement, there is at present insufficient evidence to exclude such patients from consideration of CRT therapy if they are otherwise eligible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11545/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"       \"Patient information: Cardiac resynchronization therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left ventricular lead for CRT is most commonly accomplished via a transvenous coronary sinus route (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Implantation technique'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Complications of transvenous CRT implantation include unsuccessful placement, coronary sinus or coronary vein trauma, pneumothorax,",
"      <span class=\"nowrap\">",
"       diaphragmatic/phrenic",
"      </span>",
"      nerve pacing, and infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The in-hospital mortality rate with CRT-ICD implantation is around 0.5 percent but is higher in older adults.",
"     </li>",
"     <li>",
"      One limitation in comparing CRT trials is marked disparity in response criteria used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lack of standard response criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best way to optimize AV delay has not been defined but Doppler echocardiography may be helpful. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'AV delay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with LBBB, LV pacing may be an alternative to CRT (LV and RV pacing) but there is greater evidence to support CRT. (See",
"      <a class=\"local\" href=\"#H799233\">",
"       'Left ventricular pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further development and evaluation of lead position techniques for CRT are required to ascertain the value of individualized lead placement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lead positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scar burden, particularly near the LV lead, is associated with reduced response to CRT. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Scar burden'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interruption of CRT typically results in prompt recurrence or exacerbation of HF. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Interruption of CRT'",
"      </a>",
"      above.) No single echocardiographic measure of dyssynchrony can be recommended to improve patient selection for CRT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Significance of dyssynchrony measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17795582\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Kumar for his contributions as an author to previous versions of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/1\">",
"      Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002; 39:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/2\">",
"      Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation 2003; 108:2596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/3\">",
"      Auricchio A, Abraham WT. Cardiac resynchronization therapy: current state of the art: cost versus benefit. Circulation 2004; 109:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/4\">",
"      Leclercq C, Hare JM. Ventricular resynchronization: current state of the art. Circulation 2004; 109:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/5\">",
"      Jarcho JA. Resynchronizing ventricular contraction in heart failure. N Engl J Med 2005; 352:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/6\">",
"      Burkhardt JD, Wilkoff BL. Interventional electrophysiology and cardiac resynchronization therapy: delivering electrical therapies for heart failure. Circulation 2007; 115:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/7\">",
"      Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/8\">",
"      Gras D, Mabo P, Tang T, et al. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. Pacing Clin Electrophysiol 1998; 21:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/9\">",
"      Saxon, LA, DeMarco, T, Chatterjee, K, et al, for the Vigor-CHF Investigators. Operative risk associated with chronic biventricular pacemaker implantation in advanced heart failure (abstract). Pacing Clin Electrophysiol 1998; 21:II498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/10\">",
"      Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/11\">",
"      Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/12\">",
"      McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/13\">",
"      Le&oacute;n AR, Abraham WT, Curtis AB, et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol 2005; 46:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/14\">",
"      Perisinakis K, Theocharopoulos N, Damilakis J, et al. Fluoroscopically guided implantation of modern cardiac resynchronization devices: radiation burden to the patient and associated risks. J Am Coll Cardiol 2005; 46:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/15\">",
"      Fish JM, Brugada J, Antzelevitch C. Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol 2005; 46:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/16\">",
"      Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010; 170:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/17\">",
"      Navia JL, Atik FA, Grimm RA, et al. Minimally invasive left ventricular epicardial lead placement: surgical techniques for heart failure resynchronization therapy. Ann Thorac Surg 2005; 79:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/18\">",
"      Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/19\">",
"      Steendijk P, Tulner SA, Bax JJ, et al. Hemodynamic effects of long-term cardiac resynchronization therapy: analysis by pressure-volume loops. Circulation 2006; 113:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/20\">",
"      Ermis C, Seutter R, Zhu AX, et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2005; 46:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/21\">",
"      Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 2005; 46:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/22\">",
"      Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010; 121:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/23\">",
"      Meluz&iacute;n J, Nov&aacute;k M, M&uuml;llerov&aacute; J, et al. A fast and simple echocardiographic method of determination of the optimal atrioventricular delay in patients after biventricular stimulation. Pacing Clin Electrophysiol 2004; 27:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/24\">",
"      Murphy RT, Sigurdsson G, Mulamalla S, et al. Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy. Am J Cardiol 2006; 97:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/25\">",
"      Derval N, Steendijk P, Gula LJ, et al. Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites. J Am Coll Cardiol 2010; 55:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/26\">",
"      Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006; 113:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/27\">",
"      Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007; 153:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/28\">",
"      Sweeney MO, van Bommel RJ, Schalij MJ, et al. Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation 2010; 121:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/29\">",
"      Bernheim A, Ammann P, Sticherling C, et al. Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing. J Am Coll Cardiol 2005; 45:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/30\">",
"      Knight BP, Desai A, Coman J, et al. Long-term retention of cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/31\">",
"      Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/32\">",
"      Brandt RR, Reiner C, Arnold R, et al. Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy. Eur Heart J 2006; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/33\">",
"      Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol 2011; 57:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/34\">",
"      Blanc JJ, Bertault-Valls V, Fatemi M, et al. Midterm benefits of left univentricular pacing in patients with congestive heart failure. Circulation 2004; 109:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/35\">",
"      Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/36\">",
"      Rao RK, Kumar UN, Schafer J, et al. Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation 2007; 115:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/37\">",
"      Boriani G, Kranig W, Donal E, et al. A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. Am Heart J 2010; 159:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/38\">",
"      Thibault B, Ducharme A, Harel F, et al. Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex &ge;120 milliseconds. Circulation 2011; 124:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/39\">",
"      Achilli A, Sassara M, Ficili S, et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and \"narrow\" QRS. J Am Coll Cardiol 2003; 42:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/40\">",
"      Bleeker GB, Holman ER, Steendijk P, et al. Cardiac resynchronization therapy in patients with a narrow QRS complex. J Am Coll Cardiol 2006; 48:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/41\">",
"      Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 2006; 48:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/42\">",
"      Kass DA. Predicting cardiac resynchronization response by QRS duration: the long and short of it. J Am Coll Cardiol 2003; 42:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/43\">",
"      Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol 2005; 46:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/44\">",
"      Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/45\">",
"      Kapetanakis S, Kearney MT, Siva A, et al. Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 2005; 112:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/46\">",
"      Cho GY, Song JK, Park WJ, et al. Mechanical dyssynchrony assessed by tissue Doppler imaging is a powerful predictor of mortality in congestive heart failure with normal QRS duration. J Am Coll Cardiol 2005; 46:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/47\">",
"      Penicka M, Bartunek J, De Bruyne B, et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 2004; 109:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/48\">",
"      Bordachar P, Lafitte S, Reuter S, et al. Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing. J Am Coll Cardiol 2004; 44:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/49\">",
"      Yu CM, Fung JW, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 2004; 110:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/50\">",
"      Notabartolo D, Merlino JD, Smith AL, et al. Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy. Am J Cardiol 2004; 94:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/51\">",
"      Mele D, Pasanisi G, Capasso F, et al. Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. Eur Heart J 2006; 27:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/52\">",
"      Gorcsan J 3rd, Abraham T, Agler DA, et al. Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting--a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 2008; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/53\">",
"      Lardo AC, Abraham TP, Kass DA. Magnetic resonance imaging assessment of ventricular dyssynchrony: current and emerging concepts. J Am Coll Cardiol 2005; 46:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/54\">",
"      Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity after cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol 2007; 50:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/55\">",
"      Suffoletto MS, Dohi K, Cannesson M, et al. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006; 113:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/56\">",
"      Miyazaki C, Powell BD, Bruce CJ, et al. Comparison of echocardiographic dyssynchrony assessment by tissue velocity and strain imaging in subjects with or without systolic dysfunction and with or without left bundle-branch block. Circulation 2008; 117:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/57\">",
"      Fung JW, Chan JY, Yip GW, et al. Effect of left ventricular endocardial activation pattern on echocardiographic and clinical response to cardiac resynchronization therapy. Heart 2007; 93:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/58\">",
"      Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol 2002; 40:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/59\">",
"      S&oslash;gaard P, Egeblad H, Kim WY, et al. Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol 2002; 40:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/60\">",
"      Pitzalis MV, Iacoviello M, Romito R, et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol 2005; 45:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/61\">",
"      Bleeker GB, Mollema SA, Holman ER, et al. Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation 2007; 116:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/62\">",
"      Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/63\">",
"      Gorcsan J 3rd, Oyenuga O, Habib PJ, et al. Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. Circulation 2010; 122:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/64\">",
"      Delgado V, van Bommel RJ, Bertini M, et al. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation 2011; 123:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11545/abstract/65\">",
"      Bleeker GB, Schalij MJ, Molhoek SG, et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol 2004; 15:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3500 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-E1899EF4C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11545=[""].join("\n");
var outline_f11_17_11545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPLANTATION TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING OF BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSESSING AND OPTIMIZING RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lack of standard response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AV delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lead positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Scar burden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H799294\">",
"      THINGS TO AVOID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Right atrial pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interruption of CRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H799302\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799422\">",
"      Impact on ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799233\">",
"      Left ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other measures of dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Tissue Doppler imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Significance of dyssynchrony measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17795582\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3500|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/35/15925\" title=\"figure 1\">",
"      Cardiac resynchronization leads",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=related_link\">",
"      Cardiac resynchronization therapy in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31302?source=related_link\">",
"      Dual chamber pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=related_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11546="Chronic immunomodulating therapies for myasthenia gravis";
var content_f11_17_11546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic immunomodulating therapies for myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/17/11546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/17/11546/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/17/11546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis (MG), once a uniformly disabling and even fatal disorder, can be managed effectively with current therapeutic strategies. Many patients can even achieve sustained remission. The therapeutic approach has certain general principles, but it is highly individualized for each patient. It depends upon the age of the patient, the severity of the disease, particularly dictated by respiratory or bulbar involvement, and the pace of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic immunotherapies used in the treatment of MG will be reviewed here. The general approach to the treatment of MG and to common clinical situations in patients with MG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic therapies used to treat myasthenia gravis (MG) (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic treatments: anticholinesterase agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of myasthenia gravis\", section on 'Symptomatic treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic immunomodulating treatments: glucocorticoids and other immunosuppressive drugs",
"     </li>",
"     <li>",
"      Rapid immunomodulating treatments: plasma exchange and intravenous immune globulin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of myasthenia gravis\", section on 'Rapid immunotherapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link&amp;anchor=H7#H7\">",
"       \"Myasthenic crisis\", section on 'Rapid therapies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgical treatment: thymectomy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link\">",
"       \"Thymectomy for myasthenia gravis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms can be treated with acetylcholinesterase inhibitors (also called anticholinesterase medications). These medications are all that is ever needed for some patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    bromide is the main cholinesterase inhibitor currently in use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of myasthenia gravis\", section on 'Symptomatic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, most patients with MG require some form of immunotherapy at some point in their illness, if not indefinitely. An immunomodulating agent is usually required for those patients who remain significantly symptomatic on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , or who become symptomatic again after a temporary response to pyridostigmine.",
"   </p>",
"   <p>",
"    Balancing the improvement of MG symptoms with the side effects of the immunotherapeutic agents is always a challenge for the clinician and patient. Even when immunotherapeutic drugs are used, it is common to continue the use of anticholinesterase medications in order to reduce the dosage of immunosuppressive drugs and therefore minimize their adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies and clinical experience support the efficacy of glucocorticoids in the treatment of myasthenia gravis (MG). Limited evidence from randomized, controlled trials likewise suggests that glucocorticoid treatment offers significant short-term benefit in MG compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/5\">",
"     5",
"    </a>",
"    ]. The administration of moderate or high (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) doses of glucocorticoids produces remission in about 30 percent of patients and marked improvement in another 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The onset of benefit generally begins within two to three weeks and peaks after a mean of 5.5 months.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually recommended as initial therapy for most patients with MG who require chronic immunotherapy.",
"   </p>",
"   <p>",
"    When high-dose glucocorticoids are started, up to 50 percent of patients develop a transient deterioration that can be serious [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and up to 10 percent have respiratory failure requiring mechanical ventilation. The transient worsening usually occurs 5 to 10 days after the initiation of glucocorticoids and lasts about five or six days. For this reason, glucocorticoids are most often started in high doses only in hospitalized patients who are receiving concurrent plasmapheresis or IVIG for myasthenic crisis. These latter therapies have a quick onset of action that precludes the transient worsening of MG that would otherwise occur due to the glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link&amp;anchor=H7#H7\">",
"     \"Myasthenic crisis\", section on 'Rapid therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dose escalation and tapering",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid the transient worsening that can occur early after starting high-dose glucocorticoids, an outpatient dose escalation regimen works quite effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/9\">",
"     9",
"    </a>",
"    ]. There are several equally reasonable ways to start and then taper the dose.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    can be started at 20 mg daily and then increased by 5 mg every three to five days to the target dose of 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (usually around 50 to 80 mg; no more than 100 mg). This often takes four to eight weeks. At this point, it is generally clear if there is a response to glucocorticoids. Tapering of the dose can then begin after a month or so at this dose. This can be individualized as well. If the patient has responded completely with resolution of the symptoms at a lower dose, then the dose does not need to go any higher. It is probably wise though to hold the dose at that dose level for a month or so to be certain that the response is sustained, before beginning a tapering schedule.",
"   </p>",
"   <p>",
"    Once an effective response is obtained, it is important not to taper the glucocorticoids too quickly, or else relapse is likely. Also, it should be remembered that worsening due to a reduction in dose would take at least two weeks.",
"   </p>",
"   <p>",
"    Glucocorticoid tapering can be done in two ways: as a daily or every other day regimen. Some experts advocate daily glucocorticoids, while others advocate alternate-day tapering schedules. Alternate-day glucocorticoids may have a reduced incidence of side effects, but some believe that they are not as effective as when used in a daily dosing regimen. There are no data to support the benefits of one over the other in myasthenia.",
"   </p>",
"   <p>",
"    With either regimen, the daily dose may be reduced by 5 to 10 mg each month until below 30 mg, then more slowly thereafter (5 mg per month or slower). As an example, with the every other day regimen, the taper from 80 mg daily would begin with 80 mg alternating with 60 mg, then a month later to 80 mg alternating with 40 mg, and eventually to 80 mg alternating with 0 mg. Tapering of the high-dose day would then commence. It is usually necessary to go back up to a higher dose by at least 10 to 20 mg if symptoms recur during the taper.",
"   </p>",
"   <p>",
"    Whether to use daily glucocorticoids or an alternate-day regimen is determined by the individual nature of the patient's medical health and the myasthenia. For many younger patients, those patients with little in the way of side effects, and patients with diabetes (to get a more even daily effect on blood sugars), daily dosing may be preferred.",
"   </p>",
"   <p>",
"    Many patients who respond to glucocorticoids can be effectively tapered down to approximately 10 mg per day (or 20 mg every other day) as a maintenance dose that keeps them minimally symptomatic. Young patients, in particular, tolerate such doses well with few of the side effects of these drugs. To avoid relapse, patients may need to stay on this maintenance dose for years, if not indefinitely. The relapse rate is not well defined.",
"   </p>",
"   <p>",
"    Other immunosuppressive therapies are often combined with glucocorticoids. If the glucocorticoids cannot be tapered below a reasonably acceptable level without recurrence of symptoms, or if the patient does not respond satisfactorily, then other immunotherapeutic agents are usually needed, either to supplant the glucocorticoids or as a \"glucocorticoid-sparing\" agent. This is done to allow the use of lower doses of glucocorticoids, or none at all. Commonly used in combination with or as a long-term replacement for glucocorticoids are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulsed IV methylprednisolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some have used pulsed intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (2 g over 12 hours) for exacerbations of MG, followed by 30 mg of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and a case series suggested that there is a faster onset of action and less in the way of transient worsening than with oral prednisone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/10\">",
"     10",
"    </a>",
"    ]. One randomized, controlled trial showed that there was a marked improvement in patients with MG after only one pulse compared with placebo-treated patients and that the mean duration of improvement was eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major disadvantages with chronic glucocorticoid use are their well recognized side effects. Most are not specific to myasthenia and are dose and duration of treatment dependent. These commonly include weight gain, Cushingoid facies, easy bruising and skin fragility, cataracts, aseptic necrosis of the femoral or humeral heads, hypertension, diabetes, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be advised of the potential weight gain and provided an appropriate diet if necessary. Calcium (1500 mg per day) and vitamin D (400 to 800 IU per day) supplementation should be used to reduce bone mineral loss, especially in postmenopausal women. For those most at risk for osteoporosis, bone density should be measured at the start of treatment and then every six months. If bone mineral loss has occurred, patients are generally given a bisphosphonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A histamine-2 blocker does not need to be used routinely, but it should be given in patients with a history of peptic ulcer disease or those who develop symptoms of gastritis. Blood pressure and serum glucose levels should be routinely monitored. Yearly checks for cataracts and glaucoma are also recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID (STEROID) SPARING AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is a purine analogue that inhibits the synthesis of nucleic acids. It interferes with T and B cell proliferation. Acetylcholine receptor antibodies fall with azathioprine treatment of myasthenia gravis (MG).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    significantly improves MG symptoms in most patients, but its major drawback is that the onset of any beneficial effect is delayed 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/2,12\">",
"     2,12",
"    </a>",
"    ], with a maximal effect often not until one to two years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most reported series, whether used as the primary treatment or with glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      treatment was associated with substantial improvement in 70 to 90 percent of patients with MG [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/2,12-14\">",
"       2,12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One randomized, controlled trial demonstrated the long-term efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/15\">",
"       15",
"      </a>",
"      ]. Forty-four patients with generalized MG were followed for three years and treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or azathioprine plus prednisolone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no demonstrable benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at one year. In addition, the median",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      dose to maintain remission did not differ between the two treatment groups at one year (45 mg every other day in the prednisolone alone group versus 37.5 mg every other day in the azathioprine group).",
"     </li>",
"     <li>",
"      There was significant benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at two and three years. The median",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      dose required at three years was 40 mg every other day in the prednisolone alone group, and none (0 mg) in the azathioprine group. Relapses and treatment failures were less common in the azathioprine group after one year of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies, plus many years of observational experience, emphasize that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is slow to work but is beneficial in the long term.",
"   </p>",
"   <p>",
"    Combination treatment with glucocorticoids followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    offers the advantage of relatively rapid improvement while avoiding the long-term consequences of glucocorticoid treatment. The more rapidly acting glucocorticoid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) is started for short-term effect. As the glucocorticoids are tapered, usually after a few months, azathioprine can be started. The ultimate goal is to slowly withdraw the steroids entirely. However, this can take longer than a year to achieve.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    , whether used alone or in combination with glucocorticoids, is begun at a dose of 50 mg daily for two to four weeks. If it is tolerated without systemic side effects, it can be increased by 50 mg increments every two to four weeks to a maintenance dose of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    total body weight. In most patients, this is typically 150 to 200 mg each day. Monthly monitoring of complete blood counts and liver function studies is warranted for the first six months and then less frequently if stable.",
"   </p>",
"   <p>",
"    Before starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , it is prudent to screen patients for mutations in the thiopurine methyltransferase (TPMT) gene that causes TPMT deficiency. One in 300 individuals are homozygous for a mutant allele and have very low or absent enzyme levels. These patients should not receive azathioprine because they cannot metabolize the drug and may develop life-threatening bone marrow suppression. Patients who are heterozygous for a mutant allele generally have low enzyme activity, but can tolerate azathioprine at lower than usual doses. Specific dosing recommendations for thiopurines according to TPMT genotype are available from the",
"    <a class=\"external\" href=\"file://www.pharmgkb.org/page/cpic\">",
"     Clinical Pharmacogenetics Implementation Consortium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/16\">",
"     16",
"    </a>",
"    ]. The guidelines are updated and available online at",
"    <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"     PharmGKB",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either commercially-available genotype",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phenotype (enzyme levels) testing for TPMT deficiency may be done. The TPMT erythrocyte enzyme level assay in serum is preferred because of lower cost and ready availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effect encountered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is a flu-like illness with fever, nausea, vomiting, and malaise in 10 percent and then less frequent hematological, gastrointestinal, or liver problems. The initial flu-like illness is idiosyncratic and develops within the first few weeks of treatment. The drug should be discontinued in the patient, and the symptoms quickly abate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatotoxicity, suppression of the white blood count, and pancreatitis are less common, but serious, potential adverse effects. For these reasons, it is useful to monitor with a complete blood count and liver function tests monthly for at least six months. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    dose should be decreased and the CBC monitored more frequently if the white blood count falls below 4000",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    Azathioprine should be discontinued if the white blood count falls below 3000",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/2\">",
"     2",
"    </a>",
"    ]. Azathioprine should also be discontinued if the liver function studies are more than mildly abnormal, or continue to rise. Serum amylase should be performed if symptoms develop that are consistent with pancreatitis, and azathioprine should be discontinued If the amylase is elevated in this setting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    causes a macrocytosis that increases the mean corpuscular volume (MCV). This is of little concern, but it can be used as a means to assess dosing and compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is quite uncommon in patients with MG, the risk of malignancy with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    use may be increased for non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil selectively blocks purine synthesis in lymphocytes and inhibits their proliferation. It has been increasingly used in the management of patients with MG. In some centers, including our own, mycophenolate is a second-line agent (after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) as immunotherapy to combine with and ultimately replace",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Mycophenolate is well-tolerated, with few side-effect associated treatment failures. However, the high cost of mycophenolate is prohibitive for many patients.",
"   </p>",
"   <p>",
"    Despite the clinical impression that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is beneficial, the results of randomized clinical trials suggest that mycophenolate is not effective in certain circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial, which had a nine month end-point, enrolled 172 patients with generalized MG taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &ge;20 mg daily for at least four weeks but no other immunosuppressive agent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/19\">",
"       19",
"      </a>",
"      ]. While continuing prednisone at the baseline dose, all subjects were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (2000 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/19\">",
"       19",
"      </a>",
"      ]. The dose of prednisone could then be tapered once patients had minimal or no symptoms. At 36 weeks, there was no significant effect of mycophenolate treatment for improvement on the primary composite outcome measure (44 percent, versus 39 percent for placebo). Furthermore, there was no significant effect of mycophenolate treatment on any of the secondary outcome measures, including improvement in myasthenia symptoms and glucocorticoid dose reduction.",
"     </li>",
"     <li>",
"      Another trial with a three-month duration enrolled 80 patients with generalized MG of mild to moderate severity who had received no immunomodulating therapy other than glucocorticoids within the preceding 90 days [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/20\">",
"       20",
"      </a>",
"      ]. At 12 weeks, there was no difference in outcome for the group assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (2500 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 mg daily) versus the group assigned to placebo plus prednisone (20 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/20\">",
"       20",
"      </a>",
"      ]. The investigators noted that there was an unexpectedly high rate of improvement in both groups and speculated that the high placebo response rate (77 percent) may have obscured any benefit of mycophenolate.",
"     </li>",
"     <li>",
"      In a randomized trial involving 14 patients with suboptimally treated MG, therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      led to a nonsignificant improvement in the quantitative myasthenia gravis score, the primary outcome measure, compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/21\">",
"       21",
"      </a>",
"      ]. The mycophenolate treatment group did show a statistically significant improvement in the jitter measured by single-fiber electromyography. No serious side effects were seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , these relatively short-term trials do not show a glucocorticoid-sparing effect within the first year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    use. In addition, over a three month period, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may do as well as those treated with prednisone and mycophenolate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/22\">",
"     22",
"    </a>",
"    ]. Despite the fact that these short-term prospective trials do not support the efficacy of mycophenolate in the treatment of MG, there is widespread clinical experience that supports the effectiveness of mycophenolate in the majority of patients with MG.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    in MG has been supported by several case series. Two open-label trials showed clinical improvement or a reduction in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose for 24 of 32 patients after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/23\">",
"     23",
"    </a>",
"    ] and 8 of 12 patients after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/24\">",
"     24",
"    </a>",
"    ]. No major side effects were seen in either study, and there were none that required discontinuation of the drug.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    was also evaluated in a retrospective study that included 85 patients with generalized MG who received mycophenolate doses of 1 to 3 g daily [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/25\">",
"     25",
"    </a>",
"    ]. Among them, 16 percent had disease that was refractory to therapy with glucocorticoids and at least two other immunomodulating agents. Overall, improvement with mycophenolate therapy was seen in 75 percent of patients, and half of those achieved remission. Of the nonrefractory patients, improvement occurred in 90 percent. Among 62 patients using concurrent glucocorticoids, steroid dose reduction of 50 to 100 percent was achieved in 50 percent. Among the 14 refractory patients, six improved. The mean time to first objective improvement was 11 weeks (range 4 to 40 weeks). Side effects, mostly gastrointestinal, occurred in 27 percent. Mycophenolate was discontinued due to these adverse symptoms in 6 percent. Another large retrospective study from two centers included 102 patients with acetylcholine receptor antibody-positive generalized disease who were treated with mycophenolate alone or mycophenolate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/22\">",
"     22",
"    </a>",
"    ]. Eighty percent of those followed for more than 24 months had a desirable outcome (minimal clinical manifestations or better) and the percentage of those who achieved this target began to rise as early as six months into treatment. The prednisone dose required began to fall after 12 months. After 24 months of mycophenolate treatment, 55 percent of the patients were able to come off prednisone entirely and 75 percent were on less than 7.5 mg daily.",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is 2000 mg (1000 mg twice a day). After starting at 500 mg twice a day, the dose can be increased after one to four weeks to 1000 mg twice a day, but monthly complete blood counts are usually suggested for the first six months and periodically thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are generally few with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    . The most common adverse side effects are gastrointestinal, mostly nausea or diarrhea. Leukopenia can occur, but rarely to the degree that warrants discontinuation of mycophenolate, particularly at doses (2000 mg daily or less) used in the treatment of MG. Nonetheless, monthly complete blood counts during the first six months of mycophenolate therapy, and then less frequently, are suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An unanswered question is the long-term safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    . There is no long-term experience with this agent in MG, as there is with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . In addition, it is hard to extrapolate mycophenolate risks from transplant recipients, where much higher mycophenolate doses and multiple other immunomodulating drugs are used. There is conflicting data regarding whether the risk of late malignancy, particularly lymphomas, is increased or not following therapy with mycophenolate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is an immunomodulatory agent that limits the production of interleukin-2, inhibits the function of T helper cells, and dampens T lymphocyte-dependent immune responses. It, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, has a faster onset of action than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . Clinical benefit in MG can often be appreciated as early as one to two months after starting cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Treatment with cyclosporine results in improvement in as many as 90 percent of patients, with maximal effect achieved by seven months on average [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the renal toxicity seen in some patients and the frequent interaction with other medications has made cyclosporine a third choice, after mycophenolate and azathioprine, as a long-term immunotherapeutic agent in MG.",
"   </p>",
"   <p>",
"    Small randomized, blinded, placebo-controlled trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in both newly treated patients with MG and in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -dependent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/30,31,33\">",
"     30,31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the larger trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/31\">",
"     31",
"    </a>",
"    ], 39 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -dependent MG were treated with either prednisone plus placebo or prednisone plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (in two divided doses). At six months, there was a significant improvement in strength in the cyclosporine group. This group also had a nonsignificantly lower mean prednisone dose. Over the subsequent 18 months of open-label follow-up, progressive nephrotoxicity led to discontinuation of cyclosporine in 10 percent, and cumulative side effects led to discontinuation in a total of 35 percent.",
"   </p>",
"   <p>",
"    In a study of 52 patients with generalized MG whose illness was not controlled by anticholinesterase drugs, glucocorticoids, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    resulted in moderate improvement in 33 percent and marked improvement or remission in 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and nephrotoxicity are the most common limiting adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Progressive nephrotoxicity occurs in up to 10 percent of patients. Serum creatinine and blood pressure must be monitored regularly, as well as serum trough cyclosporine levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    side effects include tremor, nausea, gingival hyperplasia, myalgias and flu-like symptoms, and hypertrichosis. The risk of malignancy with long-term use may also be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Through its metabolism via the cytochrome P450 system,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    interacts with many other medications as a substrate of CYP3A4 and an inhibitor of",
"    <span class=\"nowrap\">",
"     CYP2C8/9",
"    </span>",
"    and 3A4. Some drugs reduce the serum cyclosporine levels, whereas others raise the levels. It is important to check trough cyclosporine levels after any of these medications are added to or withdrawn from the patient's regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506), most often used after organ transplantation, is an immunosuppressive macrolide molecule similar in action to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . However, it has the advantage of being less nephrotoxic than cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a number of uncontrolled studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has been used successfully to treat MG at low doses (generally 3",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with a response rate of 67 to 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. In one series of 79 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -dependent MG, patients were switched from cyclosporine to tacrolimus and followed for a mean of 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/40\">",
"     40",
"    </a>",
"    ]. Tacrolimus doses were 0.1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    given twice daily. This was adjusted based on the tacrolimus level, aiming for 7 to 8",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The mean dose was higher at the study onset (5.5 mg daily) than at the final visit (3.6",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Pharmacologic remission was obtained in 87 percent, and prednisone could be withdrawn in all but two patients. AChR antibodies fell and strength improved significantly from baseline in this cohort.",
"   </p>",
"   <p>",
"    One randomized pilot study compared untreated de novo patients with generalized MG in two arms: one with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (n = 16) and one with prednisolone and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (n = 18). At one year, low-dose tacrolimus (3",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    resulted in a significant reduction in the prednisolone dose required to maintain minimal manifestations of the MG. None of the patients had significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    acts on the ryanodine receptor (RyR)-related sarcoplasmic calcium release to potentiate excitation-contraction coupling in skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/42\">",
"     42",
"    </a>",
"    ]. Anti-RyR antibodies are seen in some patients with MG, especially those with thymoma. In an open-label study, seven patients with myasthenia and anti-RyR antibodies received tacrolimus, and plasma levels were maintained between 2 and 9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/43\">",
"     43",
"    </a>",
"    ]. Sustained clinical improvement was reported in all seven at one year. It has been suggested that this improvement could be due to both the immunosuppressant effects of tacrolimus as well as a direct pharmacologic action on the RyR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is less nephrotoxic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and this is especially true given its use in MG at doses markedly lower than that used early after organ transplantation. Nephrotoxicity has not been a limiting factor in the experience of treating MG to date [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    include hypomagnesemia, tremor, and paresthesias. These generally resolve after adjustment of the dose, if necessary, based on serum levels and magnesium replacement. In one study there was no increase in infections in the tacrolimus group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there were three malignancies that developed (two with lung cancer and one with renal cancer). These all developed within six months of therapy, so the authors felt that this was unlikely related to the administration of tacrolimus.",
"   </p>",
"   <p>",
"    Although well tolerated in the small trials cited above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has the potential for severe side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5661854\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a monoclonal antibody against B cell membrane marker CD20. Originally used to treat B cell lymphomas, there is a good theoretical rationale for its use in MG, a B cell mediated disease. It has proven to be relatively safe in other autoimmune disorders.",
"   </p>",
"   <p>",
"    There is no randomized trial evidence regarding the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in MG. However, a large and growing number of case series support its use in patients with refractory myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/44-51\">",
"     44-51",
"    </a>",
"    ]. In these reports, the majority of patients with severe, generalized MG improved. In addition, several of these studies suggest that rituximab is particularly effective for MuSK antibody positive myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/48,50,52\">",
"     48,50,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of myasthenia gravis\", section on 'MuSK antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is well-tolerated by most patients. Minor infusion reactions are common, but serious ones may occur. Patients may be more susceptible to certain infections. Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with rituximab, but it is unknown if rituximab increases the risk of PML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254547\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is an immunosuppressant agent that decreases purine and pyrimidine synthesis and interferes with DNA synthesis. There are no randomized or open-label trials of MTX use in MG. However, based upon favorable clinical results in some patients, it has been suggested by some as a second line immunosuppressant agent in this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254554\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is soluble recombinant protein composed of TNF receptor linked to the Fc portion of human IgG1. Etanercept binds TNF and blocks its interaction with cell surface receptors. Blockade of tumor necrosis factor (TNF)&ndash;alpha, a proinflammatory cytokine, has been shown to suppress experimental autoimmune MG. There are limited data on the use of etanercept in myasthenia. In a six-month pilot trial, etanercept was administered in eight patients with MG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/54\">",
"     54",
"    </a>",
"    ]. Six of the eight improved, but one worsened. Further studies are needed to better characterize the potential efficacy and safety of this agent in MG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254150\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is an alkylating agent that reduces proliferation of both B and T cells. It can be effective in MG, but it has several serious potential side effects. Since there are effective agents with less toxicity, as detailed above, cyclophosphamide is usually reserved for the small percent of cases that are refractory to the other immunomodulating therapies.",
"   </p>",
"   <p>",
"    Administration of monthly high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has demonstrated equally good efficacy and much lower toxicity than daily oral cyclophosphamide in other autoimmune disorders, such as lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized, controlled trial of 23 patients with MG who were either poorly controlled or had significant glucocorticoid-related side effects, patients received their usual medications plus intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (initial dose 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of body surface area) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/56\">",
"     56",
"    </a>",
"    ]. Subsequent doses of cyclophosphamide were titrated according to changes in muscle strength and side effects. The dose was not modified as long as clinical improvement occurred and no side effects were observed. However, the subsequent dose was increased by 25 percent of the previous dose if there was no clinical improvement or side effects, or increased by 10 percent if the previous dose was higher than 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area. The maximum single dose was 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface area. Regardless of muscle strength, the subsequent dose was decreased by 25 percent if there were side effects or if the white blood cell count was",
"    <span class=\"nowrap\">",
"     &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or the polymorphonuclear cell count was &lt;2000 mm",
"    <sup>",
"     3",
"    </sup>",
"    .",
"    <sup>",
"    </sup>",
"    The cyclophosphamide treatments were given monthly for six months, then every other month, for a total of nine treatments. At one year, the following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant reduction in the mean daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose in the treatment group compared with the placebo group (14.4 mg versus 32.5 mg).",
"     </li>",
"     <li>",
"      Five of 12",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -treated patients were able to get off glucocorticoids altogether, but none was able to do so in the placebo group.",
"     </li>",
"     <li>",
"      There was also a significant increase in muscle strength measures in patients in the treatment arm versus the placebo patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no dropouts in the study due to toxicity of treatment. The incidence of hematologic and infectious complications was the same in both groups. During the study and two subsequent years of follow-up, there were no cases of hemorrhagic cystitis, cardiomyopathy, or pneumonitis. One",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -treated patient developed bladder carcinoma two years after the therapy was administered.",
"   </p>",
"   <p>",
"    A novel approach to refractory patients with myasthenia involves the use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as immunoablative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/57\">",
"     57",
"    </a>",
"    ]. This approach remains investigational. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Experimental treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254157\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of oral daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    use are myriad and include anorexia, nausea and vomiting, alopecia, persistent leukopenia, hemorrhagic cystitis, and increased risk of malignancies. As a result, oral daily therapy is seldom used. As noted in the studies above, monthly pulse cyclophosphamide is associated with fewer of these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The risk of late malignancy, including bladder cancer, remains a concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Experimental treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available immunotherapies for MG are effective. However, their utility is limited by their broad effects on the immune system. Their general immunosuppressive properties also underlie many of their potential serious side effects. Improved understanding of the immune events in MG should allow more focused, immune-based therapies.",
"   </p>",
"   <p>",
"    Several experimental immunologic approaches are being considered in myasthenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeting T cells involved in the disease &mdash; This approach attempts to convert antigen-presenting cells into \"guided missiles\" aimed at the acetylcholine receptor-specific T cells with the goal of eliminating those cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Utilizing the patient's own immune system to turn off the autoimmune response &mdash; This method uses the oral administration of acetylcholine receptor antigen in an attempt to induce tolerance to the offending antigen. Peptides administered orally or nasally have been successfully used in animal models of myasthenia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/60-64\">",
"       60-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunoablation &mdash; This technique utilizes high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      to remove all mature T and B lymphocytes. The aim is to \"reboot\" the immune system with the hope that the surviving marrow stem cells will mature without producing new autoantibodies.",
"      <br/>",
"      <br/>",
"      In a report of 12 patients with MG who were unresponsive to thymectomy, plasmapheresis, and immunosuppressive medications, treatment with intravenous cyclophosphamide (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      ideal body weight) daily for four days resulted in clinical improvement in all but one [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/57\">",
"       57",
"      </a>",
"      ]. Overall, clinical improvement lasted from five months to 7.5 years, and in seven patients the improvement lasted longer than one year. Most of the patients had an effective, but not sustained, remission, and required re-introduction of chronic immunosuppressant medications (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil) to maintain clinical remission. Adverse effects included nausea, vomiting, and febrile neutropenia.",
"      <br/>",
"      <br/>",
"      This type of therapy requires more investigation before it can be recommended for patients with severe, potentially life-threatening manifestations of MG that are refractory to more conventional therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complement inhibitors &mdash; These are under study because complement mediated injury to the postsynaptic membrane likely plays a major role in the pathogenesis of MG. In animal models, complement inhibitors limit the severity of experimental MG [",
"      <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent &ndash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    &ndash; depends upon many factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/17/11546/abstract/67\">",
"     67",
"    </a>",
"    ]. These include the relative contraindications to glucocorticoids (such as diabetes or advanced age), liver disease (precluding azathioprine use), renal disease (precluding cyclosporine or tacrolimus use), or leukopenia (problematic for both azathioprine and mycophenolate). The desired time for response onset also is a factor, varying from two to three weeks with prednisone to 6 to 12 months with azathioprine (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ). Cost is another important consideration, varying from $25 a year for prednisone to thousands of dollars a year for cyclosporine or mycophenolate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is an effective glucocorticoid-sparing agent. However, this effect may take a year or longer to become evident.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are reasonable alternatives. Mycophenolate is well-tolerated with few side effects, but lacks evidence of effectiveness from randomized controlled trials. Cyclosporine and tacrolimus have clinically significant toxicity.",
"   </p>",
"   <p>",
"    We add the glucocorticoid-sparing agent, or glucocorticoid replacement, when we are down to the lowest dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    that will maintain a reasonable clinical response. After the minimum time to onset of clinical response for the added immunotherapy (eg, as long as 12 months on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) has passed, we then slowly taper prednisone to as low a dose as can be achieved, preferably none at all. After the glucocorticoids have been tapered, we then try to taper",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    . Many, but certainly not all, patients can be minimally symptomatic or in remission on one immunotherapy agent alone.",
"   </p>",
"   <p>",
"    There is a small cohort of patients with severe myasthenia gravis who are refractory to, or are limited by the specific toxicities of, the first-line immunotherapies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). Some require unacceptably-high doses of glucocorticoids despite concurrent use of these agents. In these refractory patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or the addition of monthly intravenous immunoglobulin is often beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four basic therapies used to treat myasthenia gravis (MG) include symptomatic treatments (anticholinesterase agents), chronic immunotherapies, rapid immunotherapies (plasma exchange and intravenous immune globulin), and surgical treatment (thymectomy). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Therapeutic options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with MG require some form of immunotherapy at some point in their illness, if not indefinitely. Glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are the immunomodulating agents most widely used to treat MG. The onset of action varies considerably, and this plays a role in the choice of therapy (",
"      <a class=\"graphic graphic_table graphicRef70721 \" href=\"UTD.htm?4/56/5004\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapeutic options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adding immunotherapy to treat generalized MG in patients who remain significantly symptomatic on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      , or who become symptomatic after a temporary response to pyridostigmine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of myasthenia gravis\", section on 'Therapeutic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with moderate or high doses of glucocorticoids produces remission in about 30 percent of patients and marked improvement in another 50 percent. The onset of benefit generally begins within two to three weeks and peaks after a mean of five to six months. Up to 50 percent of patients have a transient deterioration that can be quite severe, occurring around 5 to 10 days after the initiation of high-dose glucocorticoid, and lasting about five or six days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest glucocorticoid treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      as the initial agent for most patients with MG who require chronic immunotherapy to induce remission (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prednisone can be started at 20 mg daily with gradual dose escalation to avoid the early transient worsening associated with high-dose glucocorticoids. Dose regimens are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose escalation and tapering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For glucocorticoid-sparing immunotherapy of MG, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      treatment as the first choice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      are reasonable alternatives for those patients who are intolerant of or unresponsive to azathioprine. However, there are no clinical trials comparing these agents head to head for the treatment of MG. All four agents appear to have some clinical efficacy, and the decision to use one or another must balance individual patient circumstances, time to drug effect, drug side effects, and cost. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Azathioprine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Mycophenolate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of myasthenia gravis\", section on 'Therapeutic approach'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      significantly improves MG symptoms in most patients, but the onset of benefit is delayed for 6 to 12 months, with a maximal effect often not seen until one to two years of treatment. Combination treatment with glucocorticoids followed by azathioprine offers the advantage of relatively rapid improvement while avoiding the long-term consequences of glucocorticoid treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      has an MG response rate equal to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in many case series, but is of unproven short-term benefit in patients on glucocorticoids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mycophenolate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      has a faster onset of action than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . Clinical benefit in MG can occur one to two months after starting cyclosporine, and improvement is seen in as many as 90 percent of patients with maximal effect by seven months on average. Renal toxicity and the frequent drug interactions are major drawbacks with cyclosporine. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      has been used successfully to treat MG at low doses. It has the theoretical advantage of less nephrotoxicity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , but there are more controlled trial data supporting the use of cyclosporine. Tacrolimus has the potential for severe side effects. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a small cohort of patients with severe myasthenia gravis who are refractory to, or are limited by the specific toxicities of, the first-line immunotherapies (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ). Some require unacceptably-high doses of glucocorticoids despite concurrent use of these agents. In these refractory patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or the addition of monthly intravenous immunoglobulin is often beneficial. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5661854\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      has serious potential side effects and is usually reserved for the small percent of patients with severe MG who are refractory to the other immunomodulating therapies, including trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and monthly intravenous immunoglobulin. &nbsp;(See",
"      <a class=\"local\" href=\"#H10254150\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/1\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/2\">",
"      Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/3\">",
"      Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/4\">",
"      Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/5\">",
"      Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; :CD002828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/6\">",
"      Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976; 26:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/7\">",
"      Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/8\">",
"      Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986; 36:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/9\">",
"      Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/10\">",
"      Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985; 42:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/11\">",
"      Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998; 97:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/12\">",
"      Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/13\">",
"      Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 1981; 377:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/14\">",
"      Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/15\">",
"      Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/16\">",
"      Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/17\">",
"      Witte AS, Cornblath DR, Schatz NJ, Lisak RP. Monitoring azathioprine therapy in myasthenia gravis. Neurology 1986; 36:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/18\">",
"      Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? Ann Neurol 2000; 47:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/19\">",
"      Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/20\">",
"      Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/21\">",
"      Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003; 998:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/22\">",
"      Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/23\">",
"      Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/24\">",
"      Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/25\">",
"      Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/26\">",
"      Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997; 54:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/27\">",
"      Haberal M, Karakayali H, Emirolu R, et al. Malignant tumors after renal transplantation. Artif Organs 2002; 26:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/28\">",
"      Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/29\">",
"      Dubal DB, Mueller S, Ruben BS, et al. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis. Muscle Nerve 2009; 39:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/30\">",
"      Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/31\">",
"      Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/32\">",
"      Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/33\">",
"      Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; :CD005224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/34\">",
"      Lavrnic D, Vujic A, Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 2005; 111:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/35\">",
"      de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/36\">",
"      Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002; 25:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/37\">",
"      Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002; 9:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/38\">",
"      Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003; 28:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/39\">",
"      Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005; 76:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/40\">",
"      Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005; 64:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/41\">",
"      Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study. Eur Neurol 2005; 53:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/42\">",
"      Timerman AP, Ogunbumni E, Freund E, et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993; 268:22992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/43\">",
"      Takamori M, Motomura M, Kawaguchi N, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004; 62:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/44\">",
"      Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/45\">",
"      Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/46\">",
"      Nelson RP Jr, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009; 10:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/47\">",
"      Stieglbauer K, Topakian R, Sch&auml;ffer V, Aichner FT. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009; 280:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/48\">",
"      Stein B, Bird SJ. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 2011; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/49\">",
"      Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011; 4:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/50\">",
"      D&iacute;az-Manera J, Mart&iacute;nez-Hern&aacute;ndez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/51\">",
"      Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 2012; 46:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/52\">",
"      Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008; 201-202:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/53\">",
"      Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/54\">",
"      Rowin J, Meriggioli MN, T&uuml;z&uuml;n E, et al. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004; 63:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/55\">",
"      McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/56\">",
"      De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/57\">",
"      Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/58\">",
"      Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005; 5:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/59\">",
"      Drachman DB, Wu JM, Miagkov A, et al. Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the \"guided missile\" strategy. Ann N Y Acad Sci 2003; 998:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/60\">",
"      Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/61\">",
"      Baggi F, Andreetta F, Caspani E, et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest 1999; 104:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/62\">",
"      Barchan D, Souroujon MC, Im SH, et al. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci U S A 1999; 96:8086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/63\">",
"      Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 1999; 104:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/64\">",
"      Sela M, Mozes E. Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/65\">",
"      Lewis RA, Lisak RP. \"Rebooting\" the immune system with cyclophosphamide: taking risks for a \"cure\"? Ann Neurol 2003; 53:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/66\">",
"      Soltys J, Kusner LL, Young A, et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009; 65:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/17/11546/abstract/67\">",
"      Wolfe GI, Gross B. Treatment review and update for myasthenia gravis. J Clin Neuromuscul Dis 2004; 6:54.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5175 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11546=[""].join("\n");
var outline_f11_17_11546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dose escalation and tapering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulsed IV methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GLUCOCORTICOID (STEROID) SPARING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5661854\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10254547\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10254554\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10254150\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10254157\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Experimental treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/56/5004\" title=\"table 1\">",
"      Therapies for MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=related_link\">",
"      Thymectomy for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_17_11547="Contraindications cryo cut SCC";
var content_f11_17_11547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to cryosurgical treatment of cutaneous squamous cell cancer (SCC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patients with abnormal cold tolerance, cold urticaria, cryoglobulinemia, cryofibrinogenemia, or Raynaud's disease/phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High risk SCCs or",
"tumors located in high risk, critical sites (nose, lips, ears,",
"periocular and periauricular areas, and genitals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCCs located on the lower legs or scalp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCCs located on free margins such as the eyelid, nasal alae, or helical rim",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCCs located near the external auditory canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors overlying nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent or ill-defined tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deeply invasive SCCs (invading muscle, bone, or cartilage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors in darkly pigmented patients",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Holt, PJ, et al, Br J Dermatol 1988;119:231, Kuflik, EG, Gage AA, J Am Acad Dermatol 1991;24:1002, Zacarian, SA, J Am Acad Dermatol 1983;9:947, Graham, GF, Cutis 1993;52:365.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11547=[""].join("\n");
var outline_f11_17_11547=null;
var title_f11_17_11548="ACC AHA exercise arrhythmia";
var content_f11_17_11548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise testing for arrhythmia evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that exercise testing for arrhythmia evaluation should be performed for the following indications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To identify the appropriate settings in patients with rate adaptive pacemakers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate patients with congenital complete heart block patients prior to initiation of increased physical activity or participation in competitive sports.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of benefit from exercise testing for arrhythmia evaluation for the following indications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate suspected exercise-induced arrhythmias.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; As part of the evaluation for medical, surgical, or ablative therapy in patients with known exercise-induced arrhythmias, including atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or opinion is less well established that exercise testing for arrhythmia evaluation is beneficial for the following indications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate ventricular premature beats in middle-aged patients without evidence of coronary artery disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To evaluate young patients with first-degree atrioventricular block, type I (Wenckebach) second degree atrioventricular block, left bundle branch block, right bundle branch block, or isolated ectopic beats prior to participation in competitive sports.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence that exercise testing for arrhythmia evaluation is not useful and may be harmful in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; As part of the routine evaluation of isolated ectopic beats in young patients.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Balady, GJ, Bricker, JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11548=[""].join("\n");
var outline_f11_17_11548=null;
var title_f11_17_11549="Physiologic Rx Malnutrition A";
var content_f11_17_11549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic basis for treatment of severe malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Affected organ or system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular system",
"       </td>",
"       <td>",
"        <p>",
"         Cardiac output and stroke volume are reduced",
"        </p>",
"        <p>",
"         Infusion of saline may cause an increase in venous pressure",
"        </p>",
"        <p>",
"         Any increase in blood volume can easily produce acute heart failure; any decrease will further compromise tissue perfusion",
"        </p>",
"        <p>",
"         Blood pressure is low",
"        </p>",
"        <p>",
"         Renal perfusion and circulation time are reduced",
"        </p>",
"        <p>",
"         Plasma volume is usually normal and red cell volume is reduced",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         If the child appears dehydrated, give ReSoMal or F-75 diet; do not give fluids intravenously unless the child is in shock",
"        </p>",
"        <p>",
"         If there is evidence of congestive heart failure, restrict blood transfusion to 10 mL/kg and give a diuretic*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Liver",
"       </td>",
"       <td>",
"        <p>",
"         Synthesis of all proteins is reduced",
"        </p>",
"        <p>",
"         Abnormal metabolites of amino acids are produced",
"        </p>",
"        <p>",
"         Capacity of liver to take up, metabolize and excrete toxins is severely reduced",
"        </p>",
"        <p>",
"         Energy production from substrates such as galactose and fructose is much slower than normal",
"        </p>",
"        <p>",
"         Gluconeogenesis is reduced, which increases the risk of hypoglycaemia during infection",
"        </p>",
"        <p>",
"         Bile secretion is reduced",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Do not give the child large meals",
"        </p>",
"        <p>",
"         Ensure that the amount of protein given does not exceed the metabolic capacity of the liver, but is sufficient to support synthesis of proteins (1-2 g/kg per day)",
"        </p>",
"        <p>",
"         Reduce the dosage of drugs that depend on hepatic disposal or are hepatotoxic",
"        </p>",
"        <p>",
"         Ensure that sufficient carbohydrate is given to avoid the need for gluconeogenesis",
"        </p>",
"        <p>",
"         Do not give iron supplements, which may be dangerous because transferrin levels are reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Genitourinary system",
"       </td>",
"       <td>",
"        <p>",
"         Glomerular filtration is reduced",
"        </p>",
"        <p>",
"         Capacity of kidney to excrete excess acid or a water load is greatly reduced",
"        </p>",
"        <p>",
"         Urinary phosphate output is low",
"        </p>",
"        <p>",
"         Sodium excretion is reduced",
"        </p>",
"        <p>",
"         Urinary tract infection is common",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Prevent further tissue breakdown by treating any infections and providing adequate energy (80-100 kcal/kg or 336-420 kJ/kg per day)",
"        </p>",
"        <p>",
"         Do not give the child more protein than is required to maintain tissues",
"        </p>",
"        <p>",
"         Ensure that high-quality proteins are given, with balanced amino acids",
"        </p>",
"        <p>",
"         Avoid nutrients that give an acid load, such as magnesium chloride",
"        </p>",
"        <p>",
"         Restrict dietary sodium",
"        </p>",
"        <p>",
"         Ensure that water intake is sufficient but not excessive",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gastrointestinal system",
"       </td>",
"       <td>",
"        <p>",
"         Production of gastric acid is reduced",
"        </p>",
"        <p>",
"         Intestinal motility is reduced",
"        </p>",
"        <p>",
"         Pancreas is atrophied and production of digestive enzymes is reduced",
"        </p>",
"        <p>",
"         Small intestinal mucosa is atrophied; activities of digestive enzymes are reduced",
"        </p>",
"        <p>",
"         Absorption of nutrients is reduced when large amounts of food are eaten",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Give the child small, frequent feeds",
"        </p>",
"        <p>",
"         If absorption is poor, increase the frequency and reduce the size of each feed",
"        </p>",
"        <p>",
"         If there is malabsorption of fat, treatment with pancreatic enzymes may be useful",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Diuretics should not be given to reduce edema in malnourished children.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11549=[""].join("\n");
var outline_f11_17_11549=null;
var title_f11_17_11550="Voltage mass relation amyloid";
var content_f11_17_11550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Low voltage-mass relationship in amyoid cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The voltage-mass relationship in patients with amyloidosis, with or without cardiac symptoms, aortic valve disease, and pericardial disease. The square represents the normal range. Patients with symptomatic cardiac amyloid (green circles and black circle) had low voltage and high mass. In comparison, pericardial disease (blue squares) was associated with low voltage and low mass, and aortic valve disease (asterisks) was associated with high voltage and high mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Carroll JD, Gaasch WH, McAdam KPWJ. Am J Cardiol 1982; 49:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11550=[""].join("\n");
var outline_f11_17_11550=null;
var title_f11_17_11551="McGrath video laryngoscope";
var content_f11_17_11551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    McGrath",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aircraft Medical. Copyright &copy;2008 Aircraft Medical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_17_11551=[""].join("\n");
var outline_f11_17_11551=null;
